#1Roche#2Roche This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', ‘estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected.#3Roche HY 2022 results Basel, 21 July 2022 Roche#4Group Severin Schwan Chief Executive Officer Roche#5HY 2022 performance Outlook Roche#6HY 2022: Good Group performance Group sales +5% driven by both divisions · Pharma portfolio performing well (+3%) outgrowing biosimilar erosion Diagnostics with strong growth momentum (+11%) including good base business growth (+6%) Key products growing strongly; new launches with significant sales potential • • • Pharma growth drivers Hemlibra, Ocrevus, Evrysdi, Phesgo and Tecentriq with strong momentum Promising new launches with Vabysmo in ophthalmology and Polivy & Lunsumio in hematology Diagnostics receives EUA for SARS-CoV-2 DUO test and BDD for Alzheimer's disease amyloid plasma panel tests*; new launches of Elecsys® HCV DUO Immunoassay and Monkeypox assays; Benchmark Ultra PLUS and Digital Pathology slide scanner Upcoming late-stage newsflow in 2022 • Pharma: Tecentriq in adjuvant HCC and neoadjuvant NSCLC; tiragolumab + Tecentriq in esophageal cancer; Venclexta in MM; Vabysmo in RVO; Susvimo in DME & DR and gantenerumab in Alzheimer's disease • Diagnostics: ElecsysⓇ IGRA SARS-CoV-2, ElecsysⓇ pTau/AB42 ratio Gen2 CSF (FDA), Digital LightCycler, cobas® 5800 (FDA), cobas pure (FDA), cobas pulse (FDA) Growth rates at CER (Constant exchange Rates); * Data will be published at AAIC in August 22 Roche 6#7HY 2022: Group sales driven by both divisions 2022 2021 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 22.3 21.7 3 3 Diagnostics Division 9.9 9.0 10 11 Roche Group 32.3 30.7 5 5 CER=Constant Exchange Rates; totals may include differences due to rounding Roche 7#8Quarterly sales performance: As guided COVID-19 sales coming down in Q2 16% 14% 12% 10% 13% 8% 6% 7% 6% 6% 4% 4% -5% 4% 4% 2% 3% 3% 0% -2% www 14%* 12% 11% 9% 9% 7% 7% 6% 6% 6% 8% 8% 7% 6% 5% 3% 1% 1% 0% -4% -6% -4% AHR¹ impact -8% -10% COVID-19 impact Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 15 15 15 15 16 16 16 16 17 17 17 17 18 18 18 18 19 19 19 19 20 20 20 20 21 21 21 21 22 22 Growth rates at CER (Constant Exchange Rates); * Q2 2020 sales severely impacted by COVID-19 pandemic onset; 1 AHR: Avastin, Herceptin, Rituxan/MabThera Roche 8#9HY 2022: Portfolio diversification progressing CHFM 30,713 Diversification of Roche business +5% at CER +64 -987 +627 + 1,576 +392 HY 2017 CHF 26.3bn -90 32,295 HY 2021 Diagnostics Diagnostics Pharma Ronapreve AHR base COVID-19 underlying sales erosion1 business sales business Fx HY 2022 HY 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022) AHR Diagnostics Other pharma Ophthalmology Infectious diseases Immunology HY 2022 CHF 32.3bn AHR Oncology AHR Neuroscience Hemophilia A Roche 9#10HY 2022: Good underlying business momentum for both divisions % CER Pharma Quarterly sales evolution 2021-2022 % CER Diagnostics Quarterly sales evolution 2021-2022 Roche +55% +55% +48% +55% +45% +45% +35% +35% +31% +24% +25% +25% +17% +18% +14% +15% +15% +9% +4% +5% +6% +4% +5% +5% +11% 3% +10% +8% +8% +2% -5% -9% 0% +1% 0% -5% 0% -15% -11% -15% Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 2021 vs. 2020 2022 vs. 2021 Q3 2021 vs. 2020 Q4 Q1 Q2 2022 vs. 2021 Pharma Pharma excl. Ronapreve -Diagnostics -Diagnostics Base business Growth rates at CER (Constant Exchange Rates) 10 10#11HY 2022: Growth of profitability and Core EPS Benefit from Ultomiris patent settlement and share repurchase Core operating profit Core EPS 40.2% 39.2% 37.9% % of sales CHFbn +9% at CER CHF 12.7 11.8 11.7 +11% at CER 10.44 10.56 11.76 CHFbn Operating free cash flow 30.3% 26.4% 17.2% 5.0 +21% at CER 8.1 9.8 Roche 2020 2021 2022 2020 2021 2022 2020 2021 2022 CER-Constant Exchange Rates 11#12Roche 2 NMEs launched in 2022: Vabysmo and Lunsumio First-in-class bispecifics launched in ophthalmology and malignant hematology Roche: Leading in bispecific antibodies TECENTRIQ™ atezolizumab VENCLEXTA venetoclax tablets ALECENSA alectinib capsules 150mg COTELLIC LUXTURNA voretigene neparvovec-rzyl for ubertal injection xofluza (balaxavir marboxil) tablets ENSPRYNG POLIVY polatumumab vedotin | 150 ROZLYTREK HEMLIBRA. emicizumab-kxwh injection for subsu OCREVUS ocrelizumab PHESGO pertuzumab/trastuzumab hyaluronidase-zz 2017 Evrysdi. risdiplam GAVRETO pralsetinib RONAPREVE casirivimab and imdevimab SuSvim o™ ranibizumab injection VABYSMO Lunsumic 2015 2016 2017 | 2018 | 2019 | 2020 2021 2022 2022 14 First bispecific mAb that bridges activated factor IX (FIXa) and FX to restore function of missing FVIII Approved for severe, moderate and mild hemophilia A and for patients with inhibitors HEMLIBRA. emicizumab-kxwh go First bispecific mAb to simultaneously target VEGF-A and Ang2 to reduce neovascularization and inflammation to stabilise vessels Approved by FDA in nAMD and DME; RVO trials ongoing • VABYSMO T cell engaging bispecific mAb that binds simultaneously to CD20 on the surface of malignant B cells and to CD3 on the surface of T cells, thereby activating T cell induced cancer cell killing • Lunsumic Approved by EMA in FL, DLBCL trials ongoing mosunetuzumab NME=new molecular entity; mAb-monoclonal antibody; VEGF-Vascular endothelial growth factor; Ang-2-Angiopoietin-2; DME-diabetic macular edema; nAMD-neovascular age-related macular degeneration; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; RVO-retinal vein occlusion 12#13HY 2022 performance Outlook Roche#142022: Upcoming newsflow Pharma Vabysmo in DME/nAMD Ongoing and Susvimo in nAMD upcoming launches Polivy in 1L DLBCL Lunsumio in 3L+ FL tiragolumab + Tecentriq studies NSCLC, Cervical, Esophageal cancer Tecentriq adjuvant studies HCC, neoadjuvant NSCLC Late stage pipeline Venclexta in MM (t11;14) read outs Vabysmo in RVO Susvimo in DMR/DR gantenerumab in Alzheimer's disease cobas 5800 (FDA) cobas pure (FDA) cobas pulse (FDA) Upcoming launches ElecsysⓇ IGRA SARS-COV-2 Diagnostics Real-time PCR molecular testing for low volume labs Serum work area analyzer for low-to-medium sized labs Device combining glucose meter and digital platform Measure T-cell release of IFN-y following simulation by SARS-COV-2 specific antigens Digital LightCycler Novel digital PCR platform Elecsys pTau/AB42 ratio Gen2 CSF (FDA) Detect amyloid disease & enable a broader availability of testing for Alzheimer's Disease Neuroscience Oncology Ophthalmology Diagnostics DME=diabetic macular edema; nAMD-neovascular age-related macular degeneration; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; NSCLC=non-small cell lung cancer; HCC-hepatocellular carcinoma; MM-multiple myeloma; RVO-retinal vein occlusion; CSF-cerebrospinal fluid; PCR-polymerase chain reaction Roche 14#152022 sales outlook confirmed Sales drivers¹ Pharma: New products with accelerating growth Diagnostics: Base business with strong growth AHR² biosimilars: Roughly CHF -2.5 bn sales erosion COVID-19 sales for Diagnostics and Pharma around CHF 5 bn 1 At Constant Exchange Rates (CER); 2 AHR=Avastin, Herceptin, Rituxan/MabThera 7 . • . Guidance stable to low-single digit group sales growth Group sales to grow high-single digit if COVID-19 sales and AHR get excluded Guidance based on a scenario with significantly reduced COVID-19 impact in H2 Roche 15#162022 outlook confirmed Group sales growth1 Core EPS growth¹ • Stable to low-single digit • Dividend outlook • 1 At Constant Exchange Rates (CER) Low- to mid-single digit Further increase dividend in Swiss francs Roche 16#17Pharmaceuticals Division Bill Anderson CEO Roche Pharmaceuticals Roche#18HY 2022: Pharmaceuticals Division sales New products compensate for biosimilar erosion CER=Constant Exchange Rates 2022 2021 Change in % CHFM CHFM CHF CER Pharmaceuticals Division 22,347 21,671 3 3 United States 11,363 10,802 5 LO 1 Europe 4,104 4,485 -8 -4 Japan 2,202 1,808 22 34 International 4,678 4,576 2 2 Roche 18#19HY 2022: Pharmaceuticals Division Core operating profit growth driven by patent settlement 2022 CHFm % sales 2022 vs. 2021 CER growth Sales 22,347 100 3% Royalties & other op. inc. 1,918 8.6 41% Cost of sales -4,430 -19.8 14% COGS+PC: +9% M&D -3,096 -13.9 4% R & D -5,729 -25.6 -3% G & A -692 -3.1 -8% Core operating profit 10,318 46.2 8% +8% in CHF CER-Constant Exchange Rates; COGS=costs of goods sold; PC-period costs Roche 19#20HY 2022: Portfolio diversification progressing Hemlibra Ocrevus Evrysdi Phesgo Tecentriq Kadcyla Alecensa Vabysmo Perjeta Xolair Polivy Ronapreve Enspryng Gazyva Gavreto Esbriet Lucentis Actemra/RoActemra Herceptin 30% 17% 106% 241% 11% 14% 19% n/a 5% 11% 91% 132% 8% n/a -14% -17% -10% -16% MabThera -21% Avastin -29% CHFM -800 -400 0 400 Absolute values and growth rates at Constant Exchange Rates (CER) 11% US ■Europe Japan International 800 Roche 20 20#21HY 2022: Oncology portfolio rejuvenation on-going YoY CER growth Phesgo (+241%) HER2 franchise HER2 franchise Herceptin Perjeta (+5%) +6% • Kadcyla (+14%) with growth ex-US due to adjuvant BC Kadcyla (+14%) · Perjeta (+5%) driven by International Tecentriq +11% Polivy (+91%) Hematology Rituxan franchise -7% Gazyva (+8%) Avastin -29% Alecensa +19% Cotellic + Cotellic (+4%) -3% Zelboraf Rozlytrek +54% Tarceva -32% Gavreto n/a CHFbn 0.0 1.0 2.0 3.0 4.0 5.0 Roche • Phesgo (CHF 325m): Conversion and geographic expansion ongoing Tecentriq Growth (+11%) driven by adjuvant NSCLC, 1L HCC and 1L SCLC Hematology franchise • Venclexta*: Growth driven by 1L AML and 1L & R/R CLL • Gazyva (+8%): Growth due to 1L FL and in 1L CLL • Polivy (+91%): Growth acceleration in the US due to R/R DLBCL; • EU approval in 1L DLBCL (POLARIX) achieved ⚫ Lunsumio: EU approval in 3L+FL achieved Alecensa Strong growth (+19%) driven by all regions CER=Constant Exchange Rates; HY 2022 Oncology sales: CHF 10.1bn; CER growth -1%; * Venclexta sales booked by AbbVie and therefore not included; Polivy in collaboration with Seagen; BC=breast cancer; HCC-hepatocellular carcinoma; SCLC=small cell lung cancer; NSCLC=non-small cell lung cancer; AML-acute myeloid leukemia; R/R CLL=relapsed/refractory chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL-diffuse large B cell lymphoma 21#22HER2+ franchise: High efficacy and safety bar established in eBC Perjeta conversion rate at 27% in early launch countries 50% Phesgo with strong global launch Global Perjeta conversion rate* Continuing to build on existing standard of care Ph III (heredERA) in 1L HER2+/ER+ mBC 40% 30% 20% 10% 0% 27% Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 ER+/HER2+ ABCa Previously untreated in the advanced setting Induction Randomization Maintenance Arm A PHESGOC Min. 4 cycles PHESGO +Taxane (4-6 cycles) of induction Minimum SD LVEF of ≥50% R 1:1 PD PHESGO Arm Bd Giredestrante Long-term follow-up Roche • Phesgo SC significantly cuts healthcare costs and resource use • HER2+/HR+ BC with distinctive disease biology • Perjeta conversion rate reaches 27% in early launch countries • P+H in eBC (APHINITY): 8-year follow up data presented at ESMO Virtual Plenary showing a 28% reduction in the risk of recurrence or death for high risk, lymph-node positive patients ⚫ Ph III (heredERA) of Phesgo + giredestrant in 1L HER2+/ER+ mBC started enrollment in Q2 2022, and aims to improve: efficacy by comprehensive blockade of both HER2 and ER pathways • treatment related QOL, with a patient centric regimen P=Perjeta; H-Herceptin; HR-Hormone receptor; HER2-Human epidermal growth factor receptor 2; BC=Breast cancer; eBC-Early breast cancer; mBC=Metastatic breast cancer; ER-Estrogen receptor; IV-Intravenous; SC=Subcutaneous; QoL-Quality of life; SD-Stable disease; LVEF=Left ventricular ejection fraction; PD-Progressive disease; *Perjeta conversion rate is based on volumes (vials) and includes all launch countries after the 2nd quarter after the launch (17 countries); Phesgo in collaboration with Halozyme; ESMO-European Society for Medical Oncology 22#23Tecentriq overview: Adjuvant program to read out in 2022/23 CHFM Tecentriq Q2 update Roche Ph III (IMvoke010) in adjuvant SCCHN continues to final analysis • YoY CER growth • +13% Japan: Sales impacted by mandatory price cut 1,000 900 800 +31% +54% 700 600 500 +146% 400 300 200 100 0 Lung franchise (NSCLC, SCLC) • . EU: Approval in adjuvant PDL1+ NSCLC achieved; Growth driven by 1L SCLC US: Strong launch in adjuvant PDL 1+ NSCLC Gl franchise (HCC) US/EU/Japan: Growth driven by 1L HCC Outlook 2022 • Further growth due to first-to-market indications Q2 19 Q2 20 Q2 21 Q222 • ■US Europe International Japan ⚫ Ph III Tecentriq adjuvant studies in HCC and neoadjuvant NSCLC reading out • ⚫ Ph III tiragolumab + Tecentriq in 1L EC reading out CER-Constant Exchange Rates; SCCHN-squamous cell carcinoma of the head and neck; NSCLC=non small cell lung cancer; SCLC-small cell lung cancer; HCC-hepatocellular cancer; EC-esophageal cancer 23#24Hematology franchise: Setting new standards of care First-in-class EU approvals in 1L DLBCL and 3L+ FL Ph III (POLARIX) Polivy + R-CHP in 1L DLBCL Progression free survival (PFS) POLIVYⓇ polatuzumab vedotin Lunsumic mosunetuzumab Ph I/II step up dosing (GO29781) Lunsumio in 3L+ FL Best percentage change from baseline in tumor SPD 100 Best percentage change from baseline in tumor SPD* Roche FDA BTD PFS (%) 100 80 60 40 40 20 Pola-R-CHP (N=440) R-CHOP (N=439) + Censored HR 0.73 (P<0.02) 95% CI: 0.57, 0.95 #+ 0 0 6 12 18 24 30 36 42 Time (months) Best change (%) from baseline in tumor SPD 80 60 40 20 -60 -80 ཎྱ ཧྨ ༈ 8 ༤ སྙ ༈ ༈ ༈ ཋ -100 CR¹ ORR¹ 60% 80% . • Polivy + R-CHP significantly prolongs PFS with a HR of 0.73 in patients with intermediate and high risk 1L DLBCL • • Safety of Polivy + R-CHP and R-CHOP comparable 60% CR rate (greater than 14% historical control) with the majority of responses lasting for at least 18 months Fixed duration treatment; Favorable tolerability profile suitable for outpatient setting (CRS low grade and cycle 1) • EU approval in 1L DLBCL achieved; Filed in US, Japan and China • EU approval in 3L+ FL achieved; Filed in US with priority review granted • Ph III (SUNMO) Polivy + Lunsumio in 2L+ SCT ineligible DLBCL FPI in Q2 2022 ⚫ Ph III (CELESTIMO) Lunsumio + lenalidomide in 2L+ FL started in Q4 2021 Tilly H. et al, ASH 2021; Budde et al. ASH 2021 (GO29781), 1. ORR by IRF; DLBCL-diffuse large B cell lymphoma; FL-follicular lymphoma; R=Rituxan; CHOP-cyclophosphamide, doxorubicin, vincristine, prednisone; CHP-cyclophosphamide, doxorubicin, prednisone; CRS-cytokine release syndrome; Polivy in collaboration with Seagen; SCT=stem cell transplant; HR-Hormon receptor; CR-complete response; ORR=overall response rate 24 24#25Hematology franchise development program Potential first-in-class & best-in-class combinations 100- 80 Ph II (NP30179) glofitamab in 3L+ DLBCL Duration of complete response by IRC POLIVYⓇ polatuzumab vedotin Lunsumic mosunetuzumab Most advanced clinical development program Roche FL ANNUAL MEETING 2022 ASCO DLBCL 3L+ 1L 2L+ FDA BTD 1L Polivy + R-CHP R/R Polivy + R+ benda 3L+ G+chemo G+ benda Lunsumio glofitamab Probability 60- 20- 0 1 2 3 4 5 6 Pts at 7 Median DoCR: NE mo (95% CI: 16.8, NE) 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Time (months) risk 61 57 55 46 45 36 34 33 28 26 25 23 21 16 14 13 12 10 10 3 1 NE Lunsumio + CHOP/ Lunsumio+CHP-Polivy glofit + R-CHOP/ glofit+Polivy-R-CHP Lunsumio + Polivy elderly/unfit glofit + GemOx* STARGLO Polivy + Lunsumio* SUNMO Primary endpoint met; CR: 39.4% in heavily pre-treated, highly refractory patients. CRs achieved were early and durable even after fixed-duration treatment (max. 12 cycles) • • Glofitamab was well tolerated with low rate of treatment discontinuations; CRS was mostly low grade • • EU: Filed in 3L+ DLBCL in Q2 2022 Lunsumio + + len CELESTIMO = Phill = approved or filed Lunsumio: Attractive profile for the outpatient setting and across a broad range of indications and settings; no hospitalization required Glofitamab: Best-in-class efficacy potential with high CR rates, durable responses and manageable CRS with fixed treatment duration Ph III development program in NHL with pivotal read-outs starting in 2023/24: Glofit+ GemOx (STARGLO) in 2L+ DLBCL; Polivy + Lunsumio (SUNMO) in 2L+ DLBCL; Lunsumio + lenalidomide (CELESTIMO) in 2L+ FL • Update on novel combinations in 1L DLBCL to be presented at ASH 2022 Dickinson M. et al., ASCO 2022; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; CR=complete response; CR=*2L+ SCT ineligible DLBCL; R/R-relapsed/refractory; len=lenalidomide; gemOx-gemcitabine + oxaliplatin; CRS-cytokine release syndrome; glofit=glofitamab; NHL-non-Hodgkin's lymphoma; SCT=stem cell transplant; IRC-independent review committee; Cl=confidence interval; R-CHP-Rituxan, cyclophosphamide, hydroxydoxorubicin, prednisone; CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone; ASH-American Society of Hematology 25#26Hemophilia A franchise: Hemlibra new global standard of care 35% US/EU-5 patient share reached CHFM YoY CER growth Roche Isth 2022 CONGRESS JULY 9-13 ISTH2022 ORG LONDON 1,200 1,000 800 600 +59% 400 >500% 200 +58% Hemophilia Q2 update +31% • Nearly 18,000 patients treated globally 0 Q2 19 Q2 20 Q2 21 Q2 22 ■US Europe International Japan CER=Constant Exchange Rates . • Hemlibra continues to penetrate across all approved patient. segments ⚫ Ph III (HAVEN 6) strong data in mild/moderate patients presented at ISTH 2022 Outlook 2022 • US/EU: Further patient share gains in non-inhibitors • EU: Label expansion to include mild/moderate patients (HAVEN 6) expected ⚫ Ph III (HAVEN 7) in infants (0-1 year) interim results expected 26#27Immunology franchise Actemra COVID-19 sales declining and first Esbriet generic competition CHFM YoY CER growth 2,500 +7% +2% +1% 2,000 -12% 1,500 1,000 500 Immunology Q2 update Gazyva: Ph III (INShore) in PNS initiated Actemra (-23%) • . Strong decline of COVID-19 driven sales • Remains leading RA monotherapy in EU-5 • Shift from IV to SC; SC sales accounting for >65% Xolair (+13%) • Remains the leader in biologics asthma market Actemra IV Xolair Q222 • Continued growth in CSU Esbriet (-21%) • US: Generic competition Outlook 2022 0 Q2 19 Q2 20 Q2 21 Rituxan/MabThera (RA) Actemra SC CellCept Esbriet Pulmozyme Other Roche . • Actemra: Limited COVID-19 sales due to fewer hospitalizations 27 CER=Constant Exchange Rates; PNS-Pediatric Nephrotic Syndrome; RA-rheumatoid arthritis; IV-intravenous; SC=subcutaneous; CSU-chronic spontaneous urticaria#28MS franchise: Ocrevus global market share reaches 21% Fenebrutinib development programs in RMS and PPMS well on track Roche YoY CER growth CHFM +17% Q2 update 1,500 • +31% 1,300 • 1,100 +12% • +59% 900 700 • 500 300 >250.000 patients treated globally No.1 treatment in US and EU-5 Higher persistence compared with patients treated with other MS treatments ⚫ Ph III (OCARINA II) for Ocrevus 6-month SC dosing started Ph III program (FENhance I/II, FENtrepid) for fenebrutinib in RMS and PPMS well on track Outlook 2022 100 Q2 19 US Q2 20 Europe Q2 21 International Q2 22 • US/EU: Further market share gains expected References: 1. Pineda E, Sheinson D, Ng C, Bonine N, Pardo G. Adherence and persistence to disease-modifying therapies for multiple sclerosis and their impact on clinical and economic outcomes in a US claims database. Presented at AAN 2021 Virtual Annual Meeting; April 17-22, 2021; CER-Constant Exchange Rates; MS-multiple sclerosis; SC=subcutaneous; RMS=relapsing MS; PPMS-primary progressive MS 28#29Roche SMA franchise: Evrysdi with strong global momentum US with >20% and Germany with >30% share CHFM 300 250 200 >500% 150 100 50 50 +347% Q2 update • YoY CER growth +65% • +189% 0 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q122 Q2 22 US Europe International Japan . >5,000 patients treated world wide (commercial, clinical trials, compassionate use) Retention rate of ~90% due to treatment satisfaction US: Growth driven by switch and naive patient starts; US approval for patients <2 months old achieved. • EU: Strong launches in early launch countries • Ph II/III (MANATEE) Evrysdi + anti-myostatin combination study started Outlook 2022 • Continued growth and market share gains over all market segments expected • EU: Label extension (<2 months old) based on Ph II CER-Constant Exchange Rates; SMA-spinal muscular atrophy; Anti-myostatin (GYM329) in collaboration with Chugai RAINBOWFISH expected 29#30Duchenne muscular dystrophy franchise update Pivotal Ph III development program expected to read out in 2023 Delandistrogene moxeparvovec NH1 R1 R2 R3 R5 R6 R7 R8 R9 R10 R11 R12 R13 R14 R15 R16 R17 R18 R19 H3 R20 R21 R22 R23 R24 H4 CR CT Ph lb ENDEAVOR (Study 103) Functional results: NSAA LSM change from baseline SAREPTA THERAPEUTICS PhI (Study 101) Roche ICNMD 2022 17TH INTERNATIONAL CONGRESS ON NEUROMUSCULAR DISEASES 5-9 July 2022 Brussels, Belgium NSAA total score over 4 years in treated patients vs. EC (unadjusted mean) 34 32 145 bp 795 bp 97 bp MHCK7 PROMOTER INTRON ITR 3,591 bp 53 bp 145 bp MICRO-DYSTROPHIN PA ITR ABD 581 582 583 2 CR AAVrh74 NSAA total score starting from mean score at baseline (mean ± SD) 2222220 0 4 8 12 24 36 52 Week LSM change from baseline in NSAA total score (mean ± SE) 5 4 3 2 10 WK 52 EC 1 year comparison Delandistrogene moxeparvovec Propensity-score-weighted EC Changes from baseline in NSAA were measured at Week 52 and compared to a propensity-score-weighted EC Commercially representative delandistrogene moxeparvovec led to improvements in motor function NNNNN WWW NSAA total score starting from mean score at baseline, +SD 16 14 Baseline Year 1 Year 2 Year 3 Year 4 Number of patients Delandistrogene moxeparvovec EC 4 21 4 4 4 21 19 20 21 A treated patients vs. EC: 9.9* Delandistrogene moxeparvovec (N=4) Propensity score-weighted EC (n=21) Targeted delivery of micro-dystrophin transgene to key muscle tissue can enable meaningful and durable functional response AAVrh74 vector: low likelihood of pre-existing immunity and high tropism for skeletal & cardiac muscles Expression potentiated by the MHCK7 promoter in cardiac & skeletal muscles • • In ENDEAVOR participants gained a mean 4.0 points in NSAA over 1 year vs baseline. The treatment difference vs an external control was 3.2 points which is clinically meaningful and highly statistically significant (p <0.0001) Consistent transduction, expression and safety demonstrated 4-year follow up for Study 101 (n=4): Patients maintained NSAA gain over 4 years at an age at which a decline would be expected (8-10 yrs) Ph III (EMBARK) on track to be fully enrolled by H2 2022; Ph III (ENVOL; study 302) in 0-3 year olds and Ph III (ENVISION, study 303) in older ambulatory / non ambulatory patients to be initiated in H2 2022 NSAA=North Star Ambulatory Assessment; LSM-least square mean(s); Ph 1/2a Trial of Delandistrogene Moxeparvovec in Patients with DMD: 4-year Update. Mendell J.R. et al., Journal of Neuromuscular Diseases, 2022: 9; s1, p. S97, PS03.01; One-year ENDEAVOR Data (Ambulatory, ≥4 to <8-year-olds): Phase 1b Trial of Delandistrogene Moxeparvovec in DMD. Lehman K. et al, Journal of Neuromuscular Diseases, 2022: 9; s1, p. S201, eP02.05.01. 30 50#31Ophthalmology franchise: Excellent Vabysmo launch Building a global ophthalmology franchise Vabysmo in nAMD and DME • anti-Ang2 anti-VEGF • • ASRS NYC ANNUAL MEETING 2022 First IVT therapy inhibiting two distinct disease pathways by simultaneously binding to Ang-2 and VEGF-A Potentially improved vascular stability and reduced retinal inflammation Vision gains and anatomical improvements achieved with 80% of patients reaching Q3M dosing or longer and >60% Q4M dosing Over 70,000 vials distributed in first 5 months of US launch Strong customer uptake with switching coming primarily from aflibercept • Broad coverage for ~80% of lives including policies at most national accounts Real world data (TRUCKEE study) presented at ASRS 2022; results consistent with efficacy and safety seen in development studies . Ph III (COMINO / BALATON) in RVO reading out in H2 2022 Global Sales USD bn Roche VABYSMO Global retina market growing to USD 15 bn 16 14 2.4 12 2.0 3.9 10 3.1 0.7 1.6 +2 0 8.8 RVO 7.8 6.2 ■DME/DR nAMD 2015 2020 2025E Market growth driven by aging population and diabetic epidemic Rapid market transition to next generation products expected • Innovative meachanism of actions to improve standard of care • Longer dosing intervals to improve compliance and treatment outcomes, as well as leading to cost savings Khanani A.M. et al., ASRS conference 2022; nAMD=neovascular age-related macular degeneration; DME-diabetic macular edema; RVO-retinal vein occlusion; IVT-intravitreal; DR-diabetic retinopathy; VEGF-Vascular endothelial growth factor; ASRS-American Society of Retinal Specialists; Q3M-every 3 months; Q4M-every 4 months; Eylea (aflibercept) is a registered trademark/product of Regeneron 31#32VABYSMO Roche Ophthalmology franchise: Vabysmo in nAMD At 112 weeks Q16W dosing increases to ≥ 60% Ph III (LUCERNE, TENAYA) in nAMD: Dosing intervals of patients at year 1 and 2 48 weeks TENAYA LUCERNE Q8W Q8W 20.3% 22.2% Q16W Q16W 44.9% 45.7% Q12W 34.0% Q12W 32.9% Q12W + Q16W 79.7% Q12W + Q16W 77.8% 112 weeks TENAYA LUCERNE ASRS NYC ANNUAL MEETING 2022 Q8W Q8W 18.8% 25.8% Q16W Q12W Q16W 59.0% 14.3% 66.9% Q12W 15.1% Q12W + Q16W 74.1% Q12W + Q16W 81.2% • New dual MoA to promote vascular stability, potentially leading to a more durable therapy with maintanance of long-term vision gains Proportion of patients achieving Q16W dosing increased from >45% at week 52 to ≥ 60% at week 112; Vabysmo given at interval of up to every 4 months achieved comparable vision gains and reductions in central subfield thickness (CST) versus aflibercept given every two months At two years of treatment Vabysmo was well tolerated. No cases of retinal vasculitis or occlusive retinal vasculitis were reported in the Ph III studies Ph Ill extension studies (AVONELLE-X in nAMD & Rhone-X in DME) for Vabysmo to generate long-term (up to 4 years) safety and tolerability data ongoing Demetriades A.-M. et al., ASRS conference 2022; nAMD-neovascular age-related macular degeneration; BCVA-best-corrected visual acuity; CST-central subfield thickness; DME-diabetic macular edema; Q16W-every 16 weeks; MoA-mechanism of action; Eylea (aflibercept) is a registered trademark/product of Regeneron 32 32#332022: Key late-stage news flow* and upcoming IR events Regulatory Phase III/ pivotal readouts Compound Vabysmo Susvimo Lunsumio (mosunetuzumab) Tecentriq Hemlibra Polivy + R-CHP glofitamab Tecentriq + tiragolumab + chemo Tecentriq + chemo Tecentriq + tiragolumab Tecentriq giredestrant Tecentriq + Avastin Venclexta + dexamethasone Tecentriq + chemo Tecentriq + tiragolumab + chemo Alecensa gantenerumab Susvimo Susvimo Indication nAMD/DME nAMD 3L+ FL Adjuvant NSCLC Mild to moderate hemophilia A 1L DLBCL 3L+ DLBCL 1L ES-SCLC Adjuvant SCCHN 1L PDL1+ NSCLC Adjuvant RCC 2/3L HR+ MBC Adjuvant HCC t(11;14) R/R MM Neoadjuvant NSCLC 1L esophageal cancer Adjuvant ALK+ NSCLC Alzheimer's disease DME DR Milestone US/EU approval US EU approval 2023 US/EU approval EU EU approval EU approval EU/US approval Ph lb NP30179 Ph III SKYSCRAPER-02 Ph III IMvoke010 Ph III SKYSCRAPER-01 Ph III IMmotion010 Ph II acelERA Ph III IMbrave050 Ph III CANOVA Ph III IMpower030 Ph III SKYSCRAPER-08 Ph III ALINA Ph III GRADUATE 1/2 Ph III PAGODA Ph III PAVILION EU x 2023 Continues to OS IA Х 2023 Virtual event Angiogenesis Monday, 14 February 16:30 to 17:45 CEST Virtual event MDA Wednesday, 16 March 16:30 to 17:30 CEST Roche ESG Day Access to Healthcare Monday, 16 May 15:00 to 16:30 CEST Virtual event ASCO Roche Pharma Day Virtual event London ASH Monday, 12 September TBA 10:00 to 15:00 BST Monday, 6 June 16:00 to 17:30 CEST * Outcome studies are event-driven: timelines may change; OS-overall survival; IA=interim analysis Roche الله 33#34Diagnostics Division Thomas Schinecker CEO Roche Diagnostics Roche#35HY 2022: Diagnostics Division sales Sales increase of +11% driven by COVID-19 testing and base business 2022 2021 Change in % CHFM CHFM CHF CER Diagnostics Division 9,948 9,042 10 11 Core Lab 3,875 3,770 3 4 Point of Care 1 2,609 1,798 45 46 Molecular Lab¹ 1,980 1,990 -1 1 Diabetes Care 832 894 -7 -5 Pathology Lab 652 590 11 10 Roche CER-Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +4%; 1 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales=90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances-21mCHF, Q2 21-23mCHF, Q3 21-23mCHF, Q4 21=20mCHF. 59 35#36HY 2022: Diagnostics Division regional sales Very strong growth in Asia Pacific and North America Roche North America +34% ~29% of divisional sales EMEA1 -14% ~33% of divisional sales Latin America +2% ~6% of divisional sales Asia Pacific +39% ~32% of divisional sales Growth rates at CER (Constant exchange Rates); 1 Europe, Middle East and Africa 36 56#37HY 2022: Diagnostics Division highlights Strong growth despite a high base in HY 2021 CHFbn YoY CER growth Core Lab 1,2 Point of Care2 Molecular Lab² Diabetes Care Pathology Lab +10% 0.0 -5% 1.0 2.0 +1% +46% EMEA 3 Asia-Pacific North America Latin America 3.0 +4% • 4.0 · Immunodiagnostics (+6%) Clinical Chemistry (+8%) • Custom biotech (-12%) • POC Immunodiagnostics (+54%) • POC Molecular³ (+75%) • Virology (+4%) . • Blood glucose monitoring (-7%) • ⚫ Insulin delivery systems (+17%) • Advanced staining (+9%) • Companion diagnostics (+26%) CER-Constant Exchange Rates; POC-point of care; 1 Underlying growth of Core Lab excluding Roche Information Solutions: +4%; 2 Sales in Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales=90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q121 LS Alliances-21mCHF, Q2 21=23mCHF, Q3 21-23mCHF, Q4 21=20mCHF; 3 EMEA-Europe, Middle East and Africa Roche 37 57#38Diagnostics Division sales growth by quarter Strong COVID-19 sales and base business growth Diagnostics Division sales growth -Base business sales growth' 55% 48% Roche 28% 31% 24% 18% 17% 18% 9% 10% 5% 2% 3% 11% -2% 1% 8% -5% 0% Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 -17% 0.1bn 0.6bn 0.6bn 1.1bn 1.2bn 1.3bn 1.0bn 1.2bn 1.9bn 1.2bn COVID-19 sales Growth rates at CER (Constant exchange Rates); 1 Quarterly sales growth excluding COVID-19 sales 38 58#39HY 2022: Diagnostics Division Strong core operating profit growth of +11% CER=Constant Exchange Rates 2022 2022 vs. 2021 CHFm % sales CER growth Sales 9,948 100 11% Royalties & other op. inc. 25 0.3 -46% Cost of sales -4,875 -49.1 14% M & D -1,363 -13.7 3% R & D -899 -9.0 11% G&A -276 -2.8 2% Core operating profit 2,560 25.7 11% +10% in CHF 50 39 Roche#40Upcoming launch of ElecsysⓇ IGRA SARS-CoV-2 Improving the understanding of immunity against SARS-CoV-2 Step1 T-Cell Stimulation Testing workflow Positive Control Negative SARS-COV-2 Control specific tube Roche Step 2 Quantification of IFN-Y (on Roche IA instrument) • Detects T-cell mediated immune response by measuring IFN-y release upon stimulation with 189 SARS-CoV-2 specific antigens, indicative of past exposure or vaccination Complements SARS-CoV-2 antibody tests to better understand host response and protective immunity May support risk stratification for progression to severe disease and/or protection Positive control: Mitogen stimulus, controls for sample quality and T-cell fitness Negative control: no stimulus, controls for baseline IFN-y level SARS-CoV-2 specific tube: contains SARS-CoV-2 specific antigens in coating, stimulates Anti- SARS-COV-2 T-Cell response Quality control passed ? SARS-CoV-2 specific IFN-y response, determines reactivity IA-Immunoassay; IFN-Y-Interferon gamma; IGRA=Interferon gamma release assay 40 40#41TIB-Molbiol SARS-CoV-2 menu for monitoring new variants Detecting major variants in hours vs a week for sequencing Roche BA.1 & BA.1.1 BA.3 XE BA.2 & BA.2.2 BA.2.12.1 BA.2.75 21K (Omicron) 21M (Omicron) 21L (Omicron) BA.5 XF 20B 21 (Delta 21A (Delta) BA.4 BA.5 is becoming the dominant SARS-CoV-2 variant Delta 41 11#42Monkeypox assays supplied to WHO Three assays developed in record time to monitor epidemiologic spread of the virus ՄԱ Pox virus illustration. ROGER HARRIS/SCIENCE PHOTO LIBRARY/GettyImages; WHO-World Health Organisation LightMix® Modular Orthopox Viruses New Detects all orthopox viruses (e.g. monkeypox, cowpox, camelpox) LightMix® Modular Monkeypox Viruses New Detects all variants of monkeypox viruses only LightMix® Modular Orthopox Subtyping New Detects all orthopox viruses. If positive, simultaneously indicate if monkeypox and differentiate West African from Central African monkeypox type Roche 42#43cobas® HPV self-sampling solution Increasing screening adherence to potentially reach 1.7bn women globally Roche 342,000 women die per year of cervical cancer, ~90% in LMIC with majority unscreened 2 FASTER cobas® HPV self- sampling solution¹ cobas® HPV test CINtec Plus Cytology CINtec® Histology iThemba Life® Self sampling Screen Triage Diagnose Disease management New 90% correlation between clinician collected endocervical and self-collected vaginal specimens¹ LMICS-Low- and middle-income countries; HPV-Human papillomavirus; 1 Available in CE market; 2 www.unaids.org/en/cervical_cancer 43#44ElecsysⓇ HCV DUO Immunoassay1 Early diagnosis of hepatitis C virus (HCV) enables optimal treatment Roche relative concentration in blood Diagnostic window period² 6-12 weeks HCV RNA/ core antigen anti-HCV antibodies # 02 4 6 8 10 12 24 weeks post-infection Testing strategies relying on first-line HCV antibody testing may lead to underdiagnoses in populations with ongoing transmission • . • 58m people being chronically infected globally (80% unaware³) and about 1.5m new infections per year Hepatitis C leading cause for liver cancer and curative treatments are available4 Shortening diagnostics window by up to 3 weeks compared to HCV antibody test Dual detection of antigen and antibody simplifies the HCV testing/screening algorithm while complementing RNA testing WHO elimination strategy aims to significantly reduce new infections and deaths by 2030 RNA: ribonucleic acid WHO: World Health Organisation; 1 Available in CE market; 2 Glynn S.A. et al. (2005). Dynamics of viremia in early hepatitis C virus infection. Transfusion 45, 994-1002. https://doi.org/10.1111/j.1537- 2995.2005.04390.x; 3 Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021: actions for impact. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. https://www.who.int/publications/i/item/9789240027077; 4 Fact Sheet. Viral Hepatitis and Liver Cancer. CDC; 2016. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/viral-hep-liver-cancer.pdf 44#45BenchMark ULTRA PLUS system¹ Next instrument generation for tissue advanced staining Optimized workflow • Shortened reagent validation • Reduced turnaround time • Fewer manual interventions Quality • Proven, industry leading stain quality . Robust detection kits 20 19 18 17 16 15 14 13 12 11 10 9 . • : BenchMark ULTRA PLUS Roche CHF 2.3bn accessible market³ CDX-Companion Diagnostics; 1 Available in CE market; 2 Not all available at launch, ramping up to full menu by the end of 2022; 3 Market book 2021 Roche Flexible solutions . View, manage, complete and print system data remotely Optimized protocols and slide staining based on individual staining drawers Broadest menu² . • 200+ ready to use or pre-dilute assays Most complete companion diagnostics assay menu 45#46VENTANA DP 600 slide scanner Enhancing digital pathology with high volume slide scanner High volume scanning 240 slide capacity (40x more than DP200) Flexible workflows improve efficiency Roche VENTANA OP BR Leverages optical system of DP 200 consistent image quality Continuous loading walk-away automation Slide scanner New Workflow software Al image analysis DP 6001 Navify App² Available in CE market; 2 Internal and third parties 46 46#47Roche analyst virtual event on diagnostics division AACC 2022 in Chicago Speakers: · Thomas Schinecker, CEO Roche Diagnostics Ann Costello, Global Head Roche Diagnostics Solutions July 26, 6-7:15pm CDT • Cindy Perettie, Head of Roche Molecular Labs AACC=Annual Scientific Meeting and Clinical Lab exposition Roche Palani Kumaresan, Head of Research & Development Roche Diagnostics Matt Sause, President & CEO Roche Diagnostics North America 47#48Key launches 2022 Area Pathology Lab Product BenchMark ULTRA PLUS DP600 Core Lab Instruments Molecular Lab POC cobasⓇ pure integrated solutions cobasⓇ 5800 Digital LightCycler cobasⓇ pulse HER2 Low Breast Pathology Lab PRAME HPV Self Sampling cobasⓇ HCV Duo Tests Core Lab Elecsys pTau/AB42 ratio Gen2 (CSF) cobasⓇ SARS-CoV-2 DUO Molecular Lab cobas® 5800 Menu Expansion Chronic Kidney Disease InSight Cervical Cancer Screening Lab Insights Digital Solutions cobasⓇ infinity edge suite Diabetes Care Lab Insights Platform Payer Dashboard mySugar Pump V2.0 Description Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency High capacity pathology slide scanner for high volume digitization applications Serum work area analyzer for low-to-medium sized labs Real-time PCR molecular testing for low volume labs Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs Handheld device combining professional Glucose Meter and a digital platform to host Roche owned and 3rd party digital clinical decision support applications Assay for diagnosis of HER2 low expression breast cancer First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer Self sample collection device for patients at home to collect sample for cervical cancer testing Antigen/antibody combined assay for faster diagnosis of hepatitis C Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer's Disease Automated RT-PCR assay for use on the cobas® 6800/8800 systems Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV) Digital solution (mobile app and dashboard) providing insights for chronic kidney disease patient management Digital solution (mobile app and workflow) improving the management of screening programs for cervical cancer Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem Market Status US & CE WW US US WW US US US & CE CE CE US US² & OUS1 US & CE CE CE 씽씽 CE Data integration platform for laboratory customers across disciplines Population-level insights via dashboard for HCPs, Admins and Payers Extended functionalities (e.g. temporary basal rate import from a connected insulin pump), expanded smartphone compatibility CE OUS3 OUS3 CE: European Conformity, US: FDA approval, WW: Worldwide including CE, US and China, OUS: Outside the US; PCR: Polymerase Chain Reaction; RT: Real Time; 1 Research Use Only; 2 EUA: Emergency Use Authorization; 3 Only selected countries Roche 48#49Finance Alan Hippe Chief Financial Officer Roche#50HY 2022 results Focus on cash and balance sheet Outlook Roche 50 50#51HY 2022: Highlights Roche Business Group sales growth of +5% driven by good performance of Pharmaceuticals and Diagnostics division ⚫ Pharma established products and new launches performing well; Diagnostics continuing with strong double-digit sales Core operating profit up +9% and Core EPS growth +11% (including +6.1%p net accretion Novartis share repurchase and 3.5%p from Ultomiris patent settlement) Cash flow • Operating Free Cash Flow of CHF 9.8bn, +21% growth driven by strong operating results and movements in net working capital . Net debt higher by CHF 2.7bn vs. Dec 31st 2021 Net financial result • Core net financial expense increased by CHF -370m driven by loss on equity securities IFRS • Net income +12% driven by the operating results and lower intangible assets amortization Growth rates at CER (Constant exchange Rates) 51#52HY 2022: Overall strong Group performance 2022 CHFM 2021 Change in % CHFM CHF CER Sales 32,295 30,713 5 5 Core operating profit 12,668 11,652 9 9 as % of sales 39.2 37.9 Core net income 10,160 9,527 7 7 as % of sales 31.5 31.0 Core EPS (CHF) 11.76 10.56 11 11 IFRS net income 9,161 8,216 12 12 as % of sales 28.4 26.8 Operating free cash flow 9,782 8,117 21 21 as % of sales 30.3 26.4 Free cash flow 7,097 6,038 18 18 as % of sales 22.0 19.7 CER-Constant Exchange Rates Roche 52 52#53HY 2022: Growing topline compensating biosimilar erosion Roche CHFM 30,713 +5% at CER +64 -987 +627 + 1,576 +392 -90 HY 2021 Diagnostics Diagnostics Pharma base COVID-19 underlying business sales business Ronapreve AHR sales erosion1 Fx HY 2021 and HY 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion (2.5bn for FY 2022) 32,295 HY 2022 53#54HY 2022: Core EPS development Strong EPS development driven by growth in operations and accretion effect Roche CHF 10.66 +11.0% +6.1 p -1.5p +2.9 p +3.5 p HY 2021 Operations¹ Ultomiris patent settlement² Net accretion Novartis share repurchase³ 11.83 4 Other HY 2022 At Constant Exchange Rates (CER); 1 Core operating profit excluding impacts from Ultomiris patent settlement, 2 Net impact from the Ultomiris patent settlement: gross income net of income tax and non- controlling interests, 3 Impact of lower number of shares partially offset by increase in interest expense, 4 Other (net) include effects from changes in financial income/expenses (incl. gains/losses on equity securities), changes in effective tax rate and changes in non controlling interests 54#55HY 2022: Group operating performance Core OP up +9% driven by higher gross profit and ROOI, OPEX stable Roche CER-Constant Exchange Rates 2022 CHFM abs. CER 2022 vs. 2021 CER growth Sales 32,295 +1,672 5% Royalties & other op. inc. 1,943 +536 38% Cost of sales -9,305 -1,119 14% M & D -4,459 -159 4% R & D -6,628 +85 -1% G & A -1,178 +63 -5% Core operating profit 12,668 +1,078 9% +9% in CHF 55#56HY 2022: Royalties and other operating income Higher income mainly driven by Ultomiris patent settlement CHFM 1,420 -43 +687 +25 -146 Royalties and other operating income increased by +38% at CER HY 2021 Royalty income CER Constant Exchange Rates Out-licensing Income (incl. Ultomiris) 1,943 Other operating income Income from disp. of products HY 2022 Roche 56 56#57HY 2022: Group Core cost of sales (COS) Increase due to PP&E reversal in 2021, volume growth and change in the Pharma/Diagnostics sales mix Roche 839 165 9,322 CHFM 8,203 184 8,387 -69 COS as % of group sales 26.7% 27.3% Pharma Division's proportion of Group sales declines from 71% to 69% 28.8% COS HY 2021 Impairments of PP&E Normalized reversal COS HY 2021 10% volume increase Pharma/ Diagnostics sales mix Other movements COS HY 2022 HY 2021 All at CER=Constant Exchange Rates; COS-Cost of Sales; PP&E = Property, plant and equipment 57 57#58HY 2022: Core operating profit and margin 47.2% 46.2% % of sales 44.1% 40.2% 37.9% 39.2% +2.3%p¹ +1.4%p¹ +9%¹ CHFM 12,668 +8%¹ 11,766 11,652 10,961 10,318 9,562 1 At CER-Constant Exchange Rates 2020 2021 2022 Roche Group Pharma Division 16.8% 25.7% 25.7% 0.0%p¹ +11%¹ 2,324 2,560 1,022 Diagnostics Division Roche 58#59HY 2022: Core net financial result Roche Higher net financial expenses driven by loss on Equity securities and higher interest expenses CHFM -186 • -220 Net financial expense increased by -370m at CER Interest expenses¹increased by +49% at CER +26 -10 -88 -80 -558 HY 2021 Equity securities Net interest income FX G/L Interest expenses¹ Other HY 2022 CER-Constant Exchange Rates; 1 incl. amortization of debt discount and net gains on interest rate derivatives 59#60HY 2022: Group Core tax rate Tax rate before resolution of tax disputes increased due to higher profits in higher tax jurisdictions Roche +0.8%p 18.5% 17.7% 0.8% 2.4% Reduction in the effective tax rate from the resolution of tax disputes Tax rate before resolution of tax disputes 16.9% Effective tax rate HY1 2021 -0.8%p Effective tax rate as reported 16.1% Effective tax rate HY1 2022 60#61HY 2022: Non-core and IFRS income Decrease in non-core operating expenses driven by lower amortisation of intangible assets due to Esbriet and lower costs for global restructuring plans 2021 2022 Change in % CHFM CHFM CHFM CHF CER Core operating profit 11,652 12,668 1,017 +9 +9 Global restructuring plans -511 -265 246 Amortisation of intangible assets -830 -468 362 Impairment of intangible assets¹ -165 -423 -258 M&A and alliance transactions -37 17 54 Legal & Environmental² -32 19 51 Total non-core operating items -1,575 -1,120 455 IFRS Operating profit 10,077 11,547 1,469 +15 +15 Total financial result & taxes -1,861 -2,386 -525 IFRS net income 8,216 9,161 944 +12 +12 CER = Constant Exchange Rates; 1 incl. goodwill; 2 incl. pension plan settlements Roche 61#62HY 2022 results Focus on cash and balance sheet Outlook Roche 62 62#63HY 2022: Operating free cash flow and margin OFCF of +21% driven by higher OP, net of cash adjustments and NWC movements Roche 38.8% % of sales 33.6% 30.3% 26.4% 23.5% +5.5%p¹ 17.2% +4.0%p¹ CHFM 1 At CER=Constant Exchange Rates 5,036 +21%¹ 9,782 8,117 2020 2021 2022 Roche Group -0.7% 13.0% 15.2% +2.1%p¹ +20%¹ 8,667 7,282 5,454 -44 Pharma Division +29%¹ 1,178 1,509 Diagnostics Division 50 63#64HY 2022: Group operating free cash flow OFCF up by +21% driven by higher Operating Profit, net of cash adjustments CHFM 8,117 +29 +1 +606 -70 +1,099 OFCF higher by +21%/+1,735m at CER 9,782 HY 2021 OP, net of cash adjustments NWC movement Investments in PP&E Investments in IA CER = Constant Exchange Rates; OP = Operating Profit; NWC: Net Working Capital; PP&E = Property, Plant & Equipment incl. increase of lease liability paid; IA = Intangible Assets Foreign HY 2022 exchange Roche 64#65HY 2022: Group net debt development Net debt higher by CHF -2.7bn compared to previous YE 2021 CHFbn Free Cash Flow CHF 7.1bn vs. 6.0bn in 2021 -18.2 +9.8 Dividends paid -7.7 Taxes Treasury -2.5 Trans. own eq. instr. -0.6 -0.2 M&A & All. trans. 0.0 Curr. Transl. & Other -1.5 -2.7 -20.9 -9.8 Roche Net debt Operating Non-Operating 31 Dec 2021 Free Cash Flow Free Cash Flow Dividends, M&A and Alliance transactions and other Net debt 30 Jun 2022 Intangible Asset Equity M&A Thereof investments in innovation: 2022 -0.3 0.0 0.0 Total -0.3 2021 -0.3 0.0 -1.9 -2.2 65#66Balance sheet 30 June 2022 Equity ratio at 33% (YE 2021: 31%) and net debt to assets at 24% (YE 2021: 20%) Roche % change in CER vs CHFbn 31 Dec 2021 92.3 86.7 -6% % change in CER vs 31 Dec 2021 92.3 86.7 -6% Cash and 13.0 6.8 -43% marketable 14% 8% Current securities 38.4 27.4 -28% 22.6 23.5 liabilities +5% 42% 32% Other current 24% 27% Non- assets current 30.4 +16% liabilities 25.6 35% 27% Net debt/ Non- current 56.7 56.4 62% 65% -1% total assets: Equity 24% (Net assets) 28.3 28.9 assets 31% 33% +5% CER Constant Exchange Rates 31 Dec 30 Jun 2021 2022 31 Dec 30 Jun 2021 2022 66#67HY 2022 results Focus on cash and balance sheet Outlook Roche 67#68Exchange rate impact on sales growth Negative impact driven by the EUR, JPY and "other Europe", partially offset by USD Roche CER sales growth HY 2022 VS. HY 2021 +5.4% +0.0p -0.8p +0.1p +1.8p -0.6p -1.0p +0.3p +5.2% CHF sales growth HY 2022 VS. HY 2021 CER EUR APAC USD LATAM JPY Other Other CHF Europe CER = Constant Exchange Rates (avg full year 2021) 68#69Low currency impact expected in 2022 CHF / USD Average YTD 2022 +2% +4% +4% +4% 0.94 0.95 0.95 0.92 0.90 Average YTD 2021 0.91 0.91 0.91 Roche Assuming the 30 June 2022 exchange rates remain stable until end of 2022, 2022 impact¹ is expected to be (%p): 0.92 0.92 0.93 0.94 0.98 0.97 0.96 0.96 0.96 0.96 0.96 0.96 Q1 HY Sep FY YTD Monthly avg fx rates 2022 Fx rates 30th June 2022 Sales -1 0 -1 -1 CHF / EUR Core -5% -6% -6% -6% operating 0 -1 1.09 1.09 profit 1.09 1.08 + 1.04 1.03 Core EPS 0 -1 1.02 1.01 1.04 1.05 1.02 1.02 1.04 1.03 1.00 1.00 1.00 1.00 1.00 1.00 Monthly avg fx rates 2022 Fx rates 30th June 2022 1 On group growth rates 69#702022 outlook Group sales growth1 Core EPS growth¹ • Stable to low-single digit • Dividend outlook • 1 At Constant Exchange Rates (CER) Low- to mid-single digit Further increase dividend in Swiss francs Roche 70#71Doing now what patients need next#72Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#73Changes to the development pipeline HY 2022 update 2 NMES: New to phase I New to phase II 1 NME: 4 Als: RG6237 latent myostatin + Evrysdi - SMA RG6351 NME - retinal disease RG6526 camonsertib - solid tumors 1 Al: RG6264 Phesgo OBI - HER2+ BC 1 NME: Removed from phase I RG6338 NME - metabolic diseases 2 Als: RG7440 ipatasertib + rucaparib - mCRPC, solid tumors RG7440 ipatasertib - prostate cancer, pretreated Status as of July 21, 2022 New to phase III RG1594 Ocrevus SC - PPMS & RMS RG6171 giredestrant + Phesgo - 1L ER+/HER2+ BC RG1450 gantenerumab - early Alzheimer's RG7828 Lunsumio (mosunetuzumab) + Polivy - 2L+ SCT ineligible DLBCL Removed from phase II Removed from phase III 1 NME: RG6173 anti-tryptase - asthma 1 Al: RG6171 giredestrant - 2/3L ER+/HER2- MBC New to registration Approvals Roche 1 NME (EU): RG7828 Lunsumio (mosunetuzumab) - 3L FL 1 AI (US): RG7916 Evrysdi SMA presymptomatic pediatric <2mo 2 Als (EU): RG7596 Polivy - 1L DLBCL RG7446 Tecentriq - NSCLC adj 73#74Roche Group development pipeline Phase I (49 NMES + 11 Als) RG6007 RG6026 RG6058 HLA-A2-WT1 x CD3 glofitamab monotherapy + combos tiragolumab combos AML RG7828 heme tumors heme & solid tumors RG6129 RG6160 RG6171 RG6076 CD19-4-1BBL combos HLA-A2-MAGE-A4 x CD3 cevostamab (FcRH5 x CD3) giredestrant (SERD) heme tumors CHU CHU Lunsumio (mosunetuzumab) monotheraphy + combos FIXa x FX RG6026 glofitamab +chemo heme tumors glypican-3 x CD3 solid tumors CHU codrituzumab hemophilia solid tumors HCC RG6058 tiragolumab + T tiragolumab +T+chemo tiragolumab +T+chemo tiragolumab +T r/r multiple myeloma CHU CD137 switch antibody solid tumors tiragolumab + T solid tumors CHU LUNA18 solid tumors RG6114 RG6156 inavolisib (mPI3K alpha inh) EGFRvIII x CD3 CHU SPYK04 solid tumors solid tumors SQZ PBMC vaccine glioblastoma solid tumors RG6287 IBD RG6180 autogene cevumeran + T solid tumors RG6341 asthma RG6185 belvarafenib (pan-RAF inh) + Cotellic + T solid tumors RG6107 RG6139 RG6180 RG6354 RG6357 crovalimab PD1 x LAG3 SPK-8011 RG6418 RG6189 FAP-CD40 ±T solid tumors selnoflast (NLRP3 inh) inflammation RG6194 runimotamab (HER2 x CD3) BC RG6315 RG7828 immunologic disorders Lunsumio (mosunetuzumab) RG6234 GPRC5D x CD3 multiple myeloma RG7880 efmarodocokin alfa SLE aGVHD RG6264 Phesgo OBI HER2+ BC RG6358 RG7601 CHU RG6149 SPK-8016 Venclexta + carfilzomib Oncolytic Type 5 adenovirus RG6006 Abx MCP astegolimab (Anti-ST2) bacterial infections RG6279 PD1-IL2v + T solid tumors RG6319 LepB inhibitor RG6299+ ASO factor B complicated urinary tract infection autogene cevumeran + pembrolizumab zinpentraxin alfa (PRM-151) hemophilia A with inhibitors to factor VIII r/r MM t(11;14) esophageal cancer COPD IgA nephropathy Phase II (22 NMES + 11 Als) Roche 1L ctDNA high risk DLBCL NSCLC 1L non-squamous NSCLC NSCLC neoadj-adj cervical cancer 1L PD-L1+mSCCHN sickle cell disease solid tumors 1L melanoma myelofibrosis hemophilia A RG6286 colorectal cancer RG7854/RG79 RG6035 BS-CD20 MAb RG6290 MAGE-A4 ImmTAC + T solid tumors RG6091 RG6292 CD25 MAb ±T solid tumors rugonersen (UBE3A LNA) multiple sclerosis Angelman syndrome TLR7 ago(3)/CPAM (2)/ 07/RG6346/ HBV RG60841 siRNA/PDL1 LNA RG6163 psychiatric disorders RG6359 SPK-3006 Pompe disease RG6323 IL15/IL15Ra-Fc + T solid tumors RG6182 RG6330 KRAS G12C solid tumors RG6237 latent myostatin RG6333 CD19 x CD28+ glofitamab r/r NHL RG6289 RG6344 BRAF inhibitor (3) solid tumors RG7637 RG6392 RG6433 SHP2i RG6440 TGFB (SOF 10) RG6526** camonsertib RG7446 Morpheus platform oncology solid tumors solid tumors solid tumors solid tumors RG6120 VEGF-Ang2 DutaFab RG7601 Venclexta + azacitidine r/r MDS RG6312 RG6351 RG6501* RG7921 CHU NME OpRegen neurodegenerative diseases neuromuscular disorders Alzheimer's neurodevelopmental disorders nAMD geographic atrophy retinal disease geographic atrophy nAMD RG6100 semorinemab Alzheimer's RG6102 BS-gantenerumab Alzheimer's RG6237 latent myostatin + Evrysdi SMA RG6416 bepranemab Alzheimer's RG7412 crenezumab familial Alzheimer's healthy pts RG7816 alogabat (GABA Aa5 PAM) ASD RG7906 ralmitaront RG7935 prasinezumab AMY109 endometriosis RG7802 cibisatamab + T solid tumors RG6147 RG6179 RG7774 galegenimab (HtrA1) RG7827 FAP-4-1BBL monotherapy + combos solid tumors RG6299+ ASO factor B schizophrenia Parkinson's geographic atrophy DME retinal disease geographic atrophy 1combination platform Status as of July 21, 2022 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other CHU Chugai managed +IONIS managed SQZ-SQZ Biotechnology managed *Lineage Cell Therapeutics managed **Repare Therapeutics managed RG-No-Roche/Genentech T=Tecentriq BS Brain Shuttle OBI-On-Body Delivery System 74#75Roche Group development pipeline RG3502 RG6026 Kadcyla + T Kadcyla + T glofitamab+chemo tiragolumab + T Phase III (10 NMES + 43 Als) Venclexta 2L+ HER-2+ PD-L1+ mBC HER-2+ eBC high-risk 2L+ DLBCL r/r MM t(11:14) RG6013 Hemlibra¹ RG7601 Venclexta + azacitidine 1L MDS RG6026 tiragolumab +T 1L esophageal cancer 1L PD-L1+ NSCLC Lunsumio (mosunetuzumab) + lenalidomide RG6396 Gavreto¹ 2L+ FL RG7596 RG7828 Polivy³ RG6058 tiragolumab + T tiragolumab + T locally advanced esophageal cancer stage III unresectable 1L NSCLC Lunsumio (mosunetuzumab) + Polivy 2L+ DLBCL RG7828 Lunsumio (mosunetuzumab)4 RG6321 Susvimo (PDS) 1 RG7853 Alecensa ALK+ NSCLC adj Vabysmo (faricimab) 1 RG3648 Xolair food allergy RG7716 crovalimab PNH Vabysmo (faricimab) 1 RG6107 RG6354 zinpentraxin alfa (PRM-151) IPF crovalimab aHUS Gazyva lupus nephritis RG6114 inavolisib (mPI3K alpha inh) 1L HR+ MBC RG7159 Gazyva giredestrant (SERD) 1L ER+/HER2-mBC Gazyva RG6171 giredestrant (SERD) RG7440 giredestrant (SERD) + Phesgo ipatasertib+abiraterone Tecentriq + platinum chemo ER+ BC adj 1L ER+/HER2+ BC Xofluza RG6152 Xofluza Tecentriq 1L CRPC NSCLC neoadj NMIBC, high risk gantenerumab RG1450 gantenerumab membranous nephropathy systemic lupus erythematosus influenza, pediatric (0-1 year) influenza direct transmission prodromal to mild Alzheimer's early Alzheimer's RG6152 RG56413+ RG6412 Xofluza RG1569 Actemra4 RG7916 Evrysdi¹ Roche Registration US & EU (4 NMES + 8 Als) glofitamab² Ronapreve² mild to moderate hemophilia A 3L+ DLBCL RET+ MTC, TC 1L DLBCL 3 L+ FL WAMD DME WAMD influenza, pediatric SARS-CoV-2 hospitalised COVID-19 pneumonia SMA pediatric <2months 1 Ocrevus higher dose Tecentriq RCC adj RG1594 Ocrevus SC Tecentriq+cabozantinib RCC adv RG7446 Tecentriq+cabozantinib T± chemo T + capecitabine or carbo/gem T + paclitaxel 2L NSCLC SCCHN adj RG6042 RG6168 RG6356 tominersen RMS & PPMS RMS & PPMS Huntington's Approved in US, filed in EU 2 Filed in the EU 3 Approved in EU 4 Approved in EU, filed in US Enspryng myasthenia gravis delandistrogene moxeparvovec (SRP-9001) DMD T + Avastin T + chemo 1L TNBC TNBC adj HCC adj RG7845 fenebrutinib RMS T=Tecentriq PDS-Port Delivery System with ranibizumab RG7845 fenebrutinib PPMS Susvimo (PDS) DME 1L MUC RG6321 Susvimo (PDS) DR New Molecular Entity (NME) Tecentriq SC Tecentriq T+ lurbinectedin 2L NSCLC ctDNA+ high-risk MIBC RG7716 1L maintenance SCLC Susvimo (PDS) Vabysmo (faricimab) Vabysmo (faricimab) WAMD, 36-week BRVO CRVO Additional Indication (Al) Oncology/Hematology Immunology Metabolism Neuroscience Ophthalmology Other Status as of July 21, 2022 Infectious Diseases 75#76NME submissions and their additional indications Projects in phase II and III RG6026 glofitamab + chemo 2L DLBCL Roche RG6026 New Molecular Entity (NME) Additional Indication (AI) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology RG6058 glofitamab + chemo 1L ctDNA+ high risk DLBCL tiragolumab + T 1L PD-L1+ cervical RG6180 autogene cevumeran 1L melanoma bepranemab RG6416 zinpentraxin alfa Alzheimer's alogabat RG6354 (PRM-151) RG7816 (GABA Aa5 PAM) cancer myelofibrosis ASD tiragolumab + T Lunsumio (mosun) + Other RG6058 locally adv esophageal RG7828 lenalidomide RG7845 fenebrutinib RMS cancer 2L FL Lunsumio (mosun) + RG6058 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU PDS-Port Delivery System with ranibizumab Mosun-mosunetuzumab *IONIS managed tiragolumab +T 1L non-sq NSCLC RG7828 Polivy 2L+ DLBCL (US) RG7845 fenebrutinib PPMS astegolimab RG6058 tiragolumab + T 1L PD-L1+mSCCHN RG6149 (anti-ST2) COPD RG7906 ralmitaront schizophrenia tiragolumab+T+/- RG6058 chemo NSCLC neoadj/adj RG6299+ ASO factor B IgA nephropathy RG7935 prasinezumab Parkinson's RG6058 tiragolumab + T Stage III unresectable RG6107 crovalimab sickle cell disease RG7907/ RG7854/ TLR7 ago (3)/CPAM (2) /siRNA/PDL1 LNA RG6321 RG6346/ Susvimo (PDS) 1L NSCLC RG6084 HBV WAMD, 36-week refill RG6026 glofitamab 3L+ DLBCL ✓ RG6058 tiragolumab + T 1L PD-L1+ NSCLC RG6107 crovalimab aHUS RG6139 PD1xLAG3 solid tumors gantenerumab RG1450 RG6147 early Alzheimer's tiragolumab +T RG6058 1L esophageal cancer (CN) RG6321 Susvimo (PDS) RG6114 inavolisib (mPI3K alpha inh) RG6171 giredestrant (SERD) semorinemab galegenimab (HtrA1) NME geographic atrophy RG6100 RG6179 Alzheimer's DME DME Susvimo 1L HR+ BC 1L ER+/HER2-mBC crovalimab zinpentraxin alfa giredestrant brain shuttle RG6107 RG6321 PNH (CN) gantenerumab RG1450 prodromal to mild RG7716 (PDS) DR (US) Vabysmo (faricimab) RG6354 (PRM-151) RG6171 (SERD) RG6102 IPF delandistrogene ER+ BC adj giredestrant (SERD) + gantenerumab Alzheimer's latent myostatin + RG6299+ ASO factor B geographic atrophy NME RG6356 Alzheimer's BRVO/CRVO moxeparvovec (SRP-9001) DMD RG6171 Phesgo RG6237 1L ER+/HER2+ BC Evrysdi SMA RG7774 retinal disease 2022 2023 2024 2025 and beyond Status as of July 21, 2022 76#77Al submissions for existing products Projects in phase II and III RG6264 RG6396 Phesgo OBI HER2+ BC Gavreto Tumor agnostic RG7446 Tecentriq SC 2L NSCLC New Molecular Entity (NME) Additional Indication (AI) Oncology/Hematology Immunology Infectious Diseases Roche Metabolism Neuroscience Ophthalmology Other Tecentriq + cabozantinib RG7446 2L NSCLC RG7446 Tecentriq + cabozantinib RCC adv Tecentriq + Avastin RG7446 HCC adj RG3502 Kadcyla + Tecentriq 2L+ HER-2+ PD-L1+ mBC Kadcyla + Tecentriq RG3502 HER-2+ eBC high-risk Tecentriq + paclitaxel RG7446 RG7446 Tecentriq² NSCLC neoadj RG7446 RG6413+ Ronapreve** RG7446 RG6412 SARS-CoV-2 hospitalized (EU) ✓ Tecentriq SCCHN adj RG1594 Ocrevus SC RMS & PPMS Tecentriq RG7446 TNBC adj Tecentriq High risk NMIBC Tecentriq+ lurbinectedin RG7446 ctDNA+ high-risk MIBC 1l maintenance SCLC Actemra Venclexta RG1569 RG7601 RG3648 COVID-19 pneumonia¹✓ r/r MM t(11:14) Xolair food allergy RG7601 Venclexta + azacitidine 1L MDS RG7159 Tecentriq ± chemo Tecentriq + capecitabine RG7446 RG7446 or carbo/gem RG6152 1L MUC Xofluza direct transmission RG7159 Gazyva lupus nephritis RG7159 TNBC Gazyva Gazyva systemic lupus erythematosus membranous nephropathy Xofluza RG7596 Polivy 1L DLBCL (US) Alecensa RG7853 RG6152 ALK+ NSCLC adj influenza, pediatric (0-1 year) RG6168 Enspryng myasthenia gravis RG1594 Ocrevus higher dose RMS & PPMS 2022 2023 2024 Status as of July 21, 2022 ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU 1Approved in EU, filed in US 2filing timeline based on data from interim analysis PDS-Port Delivery System with ranibizumab OBI-On-Body Delivery System **Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 2025 and beyond 77#78Major pending approvals 2022 RG6152 US Xofluza influenza pediatric Filed March 2020 Lunsumio (mosunetuzumab) EU Susvimo (PDS) China Rozlytrek RG6321 WAMD Filed April 2021 Vabysmo (faricimab) RG6268 ROS1+ NSCLC Filed Oct 2021 Rozlytrek RG7596 Japan-Chugai Polivy 1L DLBCL Filed Dec 2021 Gazyva RG7828 3L+ FL RG7716 Filed Dec 2021 Actemra DME Filed May 2021 Vabysmo (faricimab) RG6268 NTRK+ solid tumors Filed Nov 2021 RG7159 1L CLL Filed March 2022 RG1569 COVID-19 pneumonia Filed Jan 2022 RG7716 WAMD RG7596 Filed May 2021 Hemlibra RG6013 mild to moderate hemophilia A RG7596 Filed Oct 2021 Polivy 1L DLBCL Filed Nov 2021 Polivy r/r DLBCL Filed Dec 2021 RG6396 RG6152 RG7916 RG6413+ RG6412 RG6026 Status as of July 21, 2022 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Gavreto RET+ MTC, TC Filed Nov 2021 Xofluza influenza pediatric Filed Nov 2021 Evrysdi SMA presymptomatic pediatric <2mo Filed Nov 2021 Ronapreve** SARS-CoV-2 hospitalized Filed Jan 2022 glofitamab 3L+ DLBCL Filed April 2022 Metabolism Neuroscience Ophthalmology Other Roche PDS-Port Delivery System with ranibizumab **Ronapreve (casirivimab+imdevimab also known as REGEN-COV in the US) developed in collaboration with Regeneron Pharmaceuticals 78#79Major granted approvals 2022 US EU China Vabysmo (faricimab) RG7716 DME Jan 2022 RG7596 Polivy 1L DLBCL May 2022 RG7446 Tecentriq NSCLC adj March 2022 RG1569 Vabysmo (faricimab) RG7716 WAMD RG7446 Tecentriq NSCLC adj Actemra RG1569 RA SC RG7716 Japan-Chugai Actemra COVID-19 pneumonia Jan 2022 Vabysmo (faricimab) DME Jan 2022 June 2022 April 2022 RG1569 RG7916 Actemra GCA IV Feb 2022 Evrysdi SMA presymptomatic pediatric <2mo May 2022 Lunsumio (mosunetuzumab) March 2022 Vabysmo (faricimab) RG7828 3L+FL RG7716 WAMD June 2022 March 2022 Perjeta + Herceptin RG1273 HER-2+ CRC New Molecular Entity (NME) Additional Indication (AI) Oncology/Hematology Immunology Infectious Diseases Status as of July 21, 2022 Metabolism Neuroscience Ophthalmology Other RG7446 RG6013 RG105 March 2022 Tecentriq NSCLC adj May 2022 Hemlibra acquired Hemophilia A June 2022 Rituxan NMOSD June 2022 79 64 Roche#80Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#81Hemlibra Factor VIII mimetic for treatment of hemophilia A Indication Hemophilia A patients without inhibitors to factor VIII Roche Hemophilia A patients with and without inhibitors to Factor VIII, dosing every 4 weeks Phase/study # of patients Design Primary endpoint ☐ Status Phase III HAVEN 3 N=135 Patients on FVIII episodic treatment prior to study entry: ARM A: Hemlibra prophylaxis qw ARM B: Hemlibra prophylaxis q2w - ARM C: Episodic FVIII treatment; switch to Hemlibra prophylaxis possible after 24 weeks Patients on FVIII prophylaxis prior to study entry: ARM D: Hemlibra prophylaxis qw ■ Number of bleeds over 24 weeks FPI Q3 2016, recruitment completed Q2 2017 ▪ Study met primary and key secondary endpoints Q4 2017 FDA granted Breakthrough Therapy Designation April 2018 Data presented at WFH 2018 Filed in US (priority review) and EU in Q2 2018 Data published in NEJM 2018; 379:811-822 Phase III HAVEN 4 N=46 Multicenter, open-label, non-randomized study to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of Hemlibra administered every 4 weeks. ■ Part 1: Pharmacokinetic run-in part (N=6) Part 2: Expansion part (N=40) Number of bleeds over 24 weeks FPI Q1 2017, recruitment completed Q2 2017 Pharmacokinetic run-in data at ASH 2017 Positive interim analysis outcome reported Q4 2017 Data presented at WFH 2018 Interim data filed in US and EU in Q2 2018 Data published in Lancet Haematology 2019 Jun;6(6):e295-e305 •Approved in US Q4 2018 and EU Q1 2019 CT Identifier In collaboration with Chugai NCT02847637 ASH-American Society of Hematology; WFH-World Federation of Hemophilia; NEJM-New England Journal of Medicine NCT03020160 81#82Hemlibra Factor VIII mimetic for treatment of hemophilia A Indication Hemophilia A patients with and without inhibitors to Factor VIII Hemophilia A mild to moderate patients without inhibitors to Factor VIII Phase/study # of patients Phase III HAVEN 5 N=85 Phase III HAVEN 6 N=70 Roche • Design . Patients with Hemophilia regardless of FVIII inhibitor status on prophylactic or episodic treatment prior to study entry: . Arm A: Hemlibra prophylaxis qw Arm B: Hemlibra prophylaxis q4w • Arm C: No prophylaxis (control arm) Number of bleeds over 24 weeks Primary endpoint Status ■ FPI Q2 2018 Recruitment completed Q1 2019 Filed in China Q2 2020 ▪ Approved in China Q2 2021 Multicenter, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of Hemlibra in patients with mild or moderate Hemophilia A without FVIII inhibitors ☐ ☐ Hemlibra qw (1.5mg/kg), q2w (3.0mg/kg) or q4w (6.0mg/kg) (patients preference) Safety and efficacy ■ FPI Q1 2020 ☐ ☐ Recruitment completed Q1 2021 Interim data presented at ASH 2021 and primary data presented at ISTH 2022 ■ Filed in EU Q4 2021 CT Identifier NCT03315455 In collaboration with Chugai ASH-American Society of Hematology; ISTH=International Society on Thrombosis and Haemostasis NCT04158648 82 62 Hemophilia#83Alecensa New CNS-active inhibitor of anaplastic lymphoma kinase Indication Treatment-naïve ALK+ advanced NSCLC Phase/study # of patients ARM A: Alecensa 600mg BID Design ARM B: Crizotinib 250mg BID Primary endpoint Progression-free survival Phase III ALEX N=286 Status CT Identifier ▪ Recruitment completed Q3 2015 Primary endpoint met Q1 2017 ■ Data presented at ASCO 2017, 2018, ESMO 2017, 2018 Data published in NEJM 2017;377:829-838 " CNS data presented at ESMO 2017 ■ Final PFS and updated OS presented at ESMO 2019 ▪ Approved in US Q4 2017 (priority review) and in EU Q4 2017 NCT02075840 Adjuvant ALK+ NSCLC Phase III ALINA N=255 ARM A: Alecensa 600mg BID ☐ ARM B: Platinum-based chemotherapy Disease-free survival FPI Q3 2018 Recruitment completed Q4 2021 NCT03456076 In collaboration with Chugai ALK-anaplastic lymphoma kinase; CNS= Central nervous system; NSCLC=non-small cell lung cancer; OS-Overall survival, PFS=Progression-free survival; ASCO-American Society of Clinical Oncology; NEJM-New England Journal of Medicine; ESMO-European Society for Medical Oncology Roche 83 83 Oncology#84Kadcyla First ADC for HER2-positive breast cancer Indication HER2-positive early breast cancer (BC) high-risk patients 2L+ HER-2 positive PD-L1 positive metastatic breast cancer (mBC) HER2-positive early breast cancer (BC) high-risk patients Phase/study # of patients Phase III KATHERINE N=1,484 ☐ ARM A: Kadcyla 3.6mg/kg q3w Phase III KATE 3 N=320 ARM A: Kadcyla plus Tecentriq Design ARM B: Herceptin ◉ ARM B: Herceptin plus placebo Phase III ASTEFANIA N=1700 ▪ ARM A: Kadcyla plus Tecentriq - ARM B: Kadcyla plus placebo Primary endpoint ▪ Invasive disease-free survival Progression-free survival and overall survival ■ Invasive disease-free survival Status • Recruitment completed Q4 2015 • Stopped at pre-planned interim data analysis for efficacy Q4 2018 • Data presented at SABCS 2018 • BTD granted by FDA in Q1 2019 • US filling completed under RTOR Q1 2019 and filed in EU Q1 2019 . • Approved in US Q2 2019 and in EU Q4 2019 Data published in NEJM 2019; 380:617-628 FPI Q1 2021 FPI Q2 2021 CT Identifier In collaboration with ImmunoGen, Inc. NCT01772472 NCT04740918 NCT04873362 ADC-antibody drug conjugate; BTD=Breakthrough therapy designation; HER2-Human Epidermal growth factor Receptor 2; SABCS-San Antonio Breast Cancer Symposium; RTOR=Real time oncology review; NEJM-New England Journal of Medicine Roche 84 00 Oncology#85Perjeta First-in-class HER2 dimerization inhibitor Indication Phase/study # of patients Design Adjuvant HER2-positive breast cancer (BC) Phase III APHINITY N=4,803 ARM A: Perjeta (840mg loading dose, 420mg q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles) ARM B: Placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles) Primary endpoint Status CT Identifier ■ Invasive disease-free survival (iDFS) ப Primary endpoint met Q1 2017 Data presented at ASCO 2017 and published in NEJM 2017; 377:122-131 ■ Filed in US and EU Q3 2017 Approved in US Q4 2017 (priority review) and EU Q2 2018 6-year IDFS data presented at SABCS 2019 8-year iDFS data presented at ESMO virtual 2022 NCT01358877 HER2-Human Epidermal growth factor Receptor 2, IDFS=Invasive disease-free survival; ASCO-American Society of Clinical Oncology; NEJM-New England Journal of Medcine; SABCS-San Antonio Breast Cancer Symposium 85 Roche Oncology#86Phesgo FDC of Perjeta and Herceptin for subcutaneous administration Indication HER2-positive early breast cancer (BC) HER2-positive breast cancer (BC) Phase/study # of patients Design Primary endpoint Status Phase III FeDeriCa N=500 FDC of Perjeta and Herceptin for SC administration (Phesgo) in combination with chemotherapy in neoadjuvant/adjuvant setting ■ ARM A: Perjeta IV plus Herceptin IV plus chemotherapy ARM B: Phesgo plus chemotherapy Trough Serum Concentration (Ctrough) of Perjeta during cycle 7 Primary endpoint met Q3 2019 ■ Data presented at SABCS 2019 Data published in Lancet Oncology 2021 Jan;22(1):85-97 Phase II PHranceSCa N=160 ARM A: Perjeta and Herceptin IV followed by Phesgo ■ ARM B: Phesgo followed by IV ■ Percentage of patients who preferred Perjeta and Herceptin FDC SC FPI Q4 2018 Final analysis completed, 85% patients preferred FDC SC Data presented at ESMO 2020 Data published in Eur J Cancer 2021 Jul;152:223-232 Filed in US Dec 2019 & in EU Jan 2020; Approved in US Q2 2020 and EU Q4 2020 ☐ Phase I¹ N=144 Arm A: Phesgo administered using a handheld syringe with hypodermic needle (SC) ARM B: Phesgo administered using the on- body delivery system (OBI) ☐ AUCO-62*, Cmax** FPI Q2 2022 CT Identifier 1In collaboration with West Pharmaceuticals NCT03493854 NCT03674112 NCT05275010 *AUCO-62-comparability of area under the time-concentration curve from the start of dosing to 63 days; **Cmax=maximum serum concentration for pertuzumab and trastuzumab within Phesgo; FDC=Fixed-dose combination; Phesgo-FDC of Perjeta and Herceptin for SC administration; HER2-Human Epidermal growth factor Receptor 2, IV-intravenous; SC-Subcutaneous; ASCO=American Society of Clinical Onclogy; NEJM-New England Journal of Medcine; SABCS-San Antonio Breast Cancer Symposium; Eur J Cancer-European Journal of Cancer; ESMO-European Society for Medical Oncology 86 Roche Oncology#87Tecentriq Anti-PD-L1 cancer immunotherapy - lung cancer Indication Adjuvant NSCLC Neoadjuvant NSCLC Phase/study # of patients Design Phase III IMpower010 N=1,280 Following adjuvant cisplatin-based chemotherapy ARM A: Tecentriq ARM B: Best supportive care Phase III IMpower030 N=450 ARM A: Tecentriq plus platinum-based chemotherapy ARM B: Platinum-based chemotherapy Primary endpoint Status Disease-free survival Trial amended from PD-L1+ selected patients to all-comers FPI for all-comer population Q4 2016 Recruitment completed Q3 2018 Study met primary endpoint Q1 2021 Data presented at ASCO, WCLC and ESMO 2021 Filed in US (priority review) and EU Q2 2021 ▪ Approved in US Q4 2021 and EU Q2 2022 CT Identifier NCT02486718 Event-free survival ☐ FPI Q2 2018 Recruitment completed Q3 2021 NCT03456063 NSCLC-non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1; ASCO-American Society of Clinical Oncology; ESMO==European Society for Medical Oncology; WCLC-World Conference on Lung Cancer 87 Roche Oncology#88Roche Tecentriq Anti-PD-L1 cancer immunotherapy - lung cancer Indication 1L maintenance extensive-stage SCLC 2L NSCLC previously treated with an immune checkpoint inhibitor Phase/study # of patients Design Primary endpoint ☐ Phase III IMforte1 N=450 ARM A: Platinum-etoposide + Tecentriq followed by maintenance Tecentriq plus lurbinectedin ARM B: Platinum-etoposide + Tecentriq followed by maintenance Tecentriq Progression-free survival and overall survival Status CT Identifier ☐ FPI Q4 2021 NCT05091567 1In collaboration with Jazz Pharma NSCLC-non-small cell lung cancer; PD-L1=Programmed cell death-ligand 1; SCLC-small cell lung cancer; Phase III CONTACT-01 N=366 ☐ ARM A: Tecentriq plus cabozantinib ARM B: Docetaxel Overall survival FPI Q3 2020 Recruitment completed Q4 2021 NCT04471428 88 Oncology#89Tecentriq Anti-PD-L1 cancer immunotherapy - lung cancer Indication Phase/study # of patients 1L NSCLC Stage IV NSCLC Phase Ib/III IMscin0011 Design ◉ Primary endpoint Status Cohort A: ALK+ (Alecensa) Cohort B: RET+ (Alecensa) Phase II/III B-FAST Modular design ■ Cohort C: bTMB-high (Tecentriq) " " ☐ Cohort D: ROS1+ (Rozlytrek) Cohort E: BRAF+ (Zelboraf plus Cotellic plus Tecentriq) Cohort F: EGFR Exon 20+ (Tecentriq, Avastin, carboplatin, pemetrexed) Cohort G: GDC-6036 or Docetaxel Cohort A/B/D: Objective response rate Cohort C/D: Progression-free survival Cohort E: Time in response Phase lb N=371 Dose finding, Tecentriq SC followed by Tecentriq IV Phase III " 2L NSCLC non inferiority of Tecentriq SC vs Tecentriq IV Observed concentration of Tecentriq in serum at cycle 1 - Cohort F: Investigator-assessed objective response rate " FPI Q3 2017 Recruitment completed for cohort A Q3 2018 and cohort C Q3 2019 Cohort A: primary endpoint met Q3 2019; approved in US Q1 2021 ■ Cohort C: did not show statistical significance for primary endpoint, data presented at ESMO 2021 ☐ FPI Q4 2018 FPI in phase III part Q4 2020 Recruitment completed Q1 2022 ▪ Cohort F: FPI Q2 2021 CT Identifier NCT03178552 NCT03735121 ¹SC with Halozyme's rHuPH20/ Halozyme's human hyaluronidase ALK-Anaplastic lymphoma kinase; BRAF-V-raf murine sarcoma viral oncogene homolog B; bTMB-Blood-based tumor mutational burden; EGFR-Epidermal growth factor receptor; IV-intravenous; NSCLC=non-small cell lung cancer; PD-L1=Programmed cell death-ligand 1; RET-Rearranged during transfection; ROS1-C-ros oncogene 1; SC-Subcutaneous, IV-Intravenous; ESMO-European Society for Medical Oncology 89 Roche Oncology#90Tecentriq Anti-PD-L1 cancer immunotherapy - SCCHN and melanoma Indication Phase/study # of patients Design Primary endpoint Status CT Identifier ARM A: Tecentriq 1200mg q3w ARM B: Placebo Event-free survival and overall survival FPI Q1 2018 Recruitment completed Q1 2020 Adjuvant squamous cell carcinoma of the head and neck (SCCHN) Phase III IMvoke010 N=406 NCT03452137 Roche ¹In collaboration with Exelixis; 2Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; ³ Project Orbis-FDA framework for concurrent submission and review of oncology products among international partners SCCHN-squamous cell carcinoma of the head and neck; PD-L1-Programmed cell death-ligand 1; AACR-American Association for Cancer Research 90 00 Oncology#91Tecentriq Anti-PD-L1 cancer immunotherapy - urothelial carcinoma Indication 1L metastatic urothelial carcinoma (UC) High-risk non-muscle-invasive bladder cancer (MIBC) ctDNA+, high-risk muscle-invasive bladder cancer (MIBC) Phase/study # of patients Design Primary endpoint " " " Status Phase III IMvigor 130 N=1,200 ARM A: Tecentriq plus gemcitabine and carboplatin or cisplatin ARM B: Tecentriq monotherapy ▪ ARM C: Placebo plus gemcitabine and carboplatin or cisplatin Progression-free survival, overall survival and safety FPI Q3 2016 FPI for arm B (amended study) Q1 2017 Recruitment completed Q3 2018 Study met co-primary endpoint of PFS Q3 2019 ■ Data presented at ESMO 2019 and AACR 2021 Data published in Lancet 2020 May 16;395(10236):1547-1557 Phase III ALBAN N=516 ARM A: BCG induction and maintenance ■ ARM B: Tecentriq plus BCG induction and maintenance Recurrence-free survival FPI Q4 2018 CT Identifier NCT02807636 NCT03799835 Phase III IMvigor011 N=495 ▪ ARM A: Tecentriq monotherapy " ▪ ARM B: Placebo Recurrence-free survival ■ FPI Q2 2021 NCT04660344 BCG-Bacille Calmette-Guérin; PD-L1-Programmed cell death-ligand 1; PFS-Progression-free survival; AACR-American Association for Cancer Research; ESMO-European Society for Medical Oncology Roche 91 97 Oncology#92Tecentriq Anti-PD-L1 cancer immunotherapy - renal cell cancer Indication Adjuvant renal cell carcinoma (RCC) Roche Advanced renal cell carcinoma (RCC) after immune checkpoint inhibitor treatment Phase III IMmotion010 Phase/study # of patients ARM A: Tecentriq monotherapy ARM B: Placebo Design N=778 Primary endpoint ■ Investigator-assessed disease-free survival Status CT Identifier ☐ Phase III Contact-031 N=500 ARM A: Tecentriq plus cabozantinib ARM B: Cabozantinib ■ Progression-free survival and overall survival FPI Q1 2017 Recruitment completed Q1 2019 Study did not meet its primary endpoint of DFS Q2 2022 FPI Q3 2020 Recruitment completed Q4 2021 1In collaboration with Exelixis PD-L1-Programmed cell death-ligand 1; DFS=Disease-free survival NCT03024996 NCT04338269 92 Oncology#93Tecentriq Anti-PD-L1 cancer immunotherapy - hepatocellular carcinoma Indication 1L hepatocellular carcinoma (HCC) Adjuvant hepatocellular carcinoma (HCC) Phase/study Phase III IMbrave 150 # of patients N=501 ARM A: Tecentriq plus Avastin ARM B: Sorafenib Design Primary endpoint Status CT Identifier Overall survival and progression free survival FPI Q1 2018 Recruitment completed Q1 2019 Data presented at ESMO Asia 2019 ■ US filing completed under RTOR Q1 2020; filed in EU Q1 2020 ■ Data published in NEJM 2020;382:1894-1905 Approved in US Q2 2020 and EU Q4 2020 NCT03434379 Phase III IMbrave050 N=668 ■ ARM A: Tecentriq plus Avastin ARM B: Active surveillance Recurrence-free survival FPI Q4 2019 Recruitment completed Q4 2021 PD-L1-Programmed cell death-ligand 1; ESMO-European Society for Medical Oncology; NEJM-New England Journal of Medicine; RTOR=Real time oncology review NCT04102098 93 Roche Oncology#94Tecentriq Anti-PD-L1 cancer immunotherapy - breast cancer Indication Phase/study # of patients Design Phase III IMpassion 130 N=902 ARM A: Tecentriq plus nab-paclitaxel ARM B: Placebo plus nab-paclitaxel Previously untreated metastatic triple negative breast cancer (TNBC) Phase III IMpassion 132 N=572 ARM A: Tecentriq plus capecitabine or carbo/gem ARM B: Placebo plus capecitabine or carbo/gem Primary endpoint Progression-free survival and overall survival (co-primary endpoint) ■ Study met co-primary endpoint of PFS in both PD-L1+ and ITT populations Q3 2018 ■ Overall survival FPI Q1 2018 " Primary PFS and interim OS data presented at ESMO 2018 and ASCO 2019 Data published in NEJM 2018; 379:2108-2121 Status US accelerated approval Q1 2019 - US indication voluntarily withdrawn Q3 2021 CT Identifier ■ Approved in EU Q3 2019 Final OS presented at ESMO Asia 2020 NCT02425891 NCT03371017 Carbo/gem-gemcitabine and carboplatin; ITT-Intention to treat; PD-L1-Programmed cell death-ligand 1; PFS-Progression-free survival; OS-Overall survival; ESMO-European Society for Medical Oncology; ASCO=American Society of Clinical Oncology; NEJM=New England Journal of Medicine Roche 24 94 Oncology#95Tecentriq Anti-PD-L1 cancer immunotherapy - breast cancer Indication Neoadjuvant triple negative breast cancer (TNBC) Adjuvant triple negative breast cancer (TNBC) Phase/study # of patients Design Phase III IMpassion031 N=333 ARM A: Tecentriq plus nab-paclitaxel ARM B: Placebo plus nab-paclitaxel Primary endpoint Status ■ Percentage of participants with pathologic complete response FPI Q3 2017 Recruitment completed Q2 2018 Study met primary endpoint Q2 2020 ■ Data presented at ESMO 2020 Data published in Lancet 2020;396 (10257):1090-1100 Filed in EU Q4 2020 - application withdrawn Q3 2021 CT Identifier NCT03197935 PD-L1-Programmed cell death-ligand 1; ESMO-European Society for Medical Oncology Phase III IMpassion030 N=2,300 ▪ ARM A: Tecentriq plus paclitaxel followed by AC followed by Tecentriq plus AC, followed by Tecentriq maintenance ARM B: Placebo plus paclitaxel followed by AC followed by placebo Invasive disease-free survival FPI Q3 2018 NCT03498716 Roche 95 Oncology#96Roche Venclexta Novel small molecule Bcl-2 selective inhibitor - chronic lymphocytic leukemia Indication Untreated chronic lymphocytic leukemia (CLL) patients with coexisting medical conditions Phase III CLL14 Relapsed or refractory chronic lymphocytic leukemia (CLL) Untreated fit chronic lymphocytic leukemia (CLL) patients Phase/study # of patients N=445 ARM A: Venclexta plus Gazyva ARM B: Chlorambucil plus Gazyva Design Phase III MURANO N=389 ARM A: Venclexta plus Rituxan ARM B: Rituxan plus bendamustine Phase III CristaLLo N=165 ARM A: Venclexta plus Gazyva ARM B: Fludarabine plus cyclophosphamide plus Rituxan or bendamustine plus Rituxan Primary endpoint Status CT Identifier Progression-free survival Study met primary endpoint at pre-specified interim analysis Q4 2018 BTD granted by FDA Q1 2019 ■ US filing completed under RTOR Q1 2019 ■ Filed in EU Q2 2019 Data presented at ASCO 2019, ASH 2019, ASH 2020 and EHA 2021 and EHA 2022 Data published in NEJM 2019; 380:2225-2236 Approved US Q2 2019 and EU Q1 2020 NCT02242942 ☐ Progression-free survival MRD negativity rate in peripheral blood at 15 months Study met primary endpoint at interim analysis ☐ FPI Q2 2020 ☐ Data presented at ASH 2017 Filed in US Q4 2017 and EU Q1 2018 Data published in NEJM 2018; 378:1107-20 Updated data presented at ASCO 2018, ASH 2019 and ASH 2020 Approved in US Q2 2018 (priority review) EU approval Q4 2018 NCT02005471 NCT04285567 Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute Bcl-2-B-cell lymphoma 2; BTD=Breakthrough therapy designation; CLL=chronic lymphocytic leukemia; MRD-Minimal Residual Disease; ASH-American Society of Hematology; ASCO=American Society of Clinical Oncology; EHA-European Hematology Association; RTOR=Real time oncology review; NEJM-New England Journal of Medicine 96 Oncology#97Venclexta Novel small molecule Bcl-2 selective inhibitor - multiple myeloma Indication Phase/study # of patients Design Primary endpoint Status CT Identifier Relapsed or refractory multiple myeloma (MM) Roche Phase I N=117 " Dose escalation cohort: Venclexta dose escalation " ▪ Safety expansion cohort (t11;14): Venclexta expansion Combination: Venclexta plus dexamethasone Phase Ib/II N=120 ■ Venclexta plus carfilzomib plus dexamethasone in t(11;14) positive r/r MM Phase III CANOVA N=244 ■ Venclexta plus dexamethazone vs pomalidomide plus dexamethasone in t(11;14) positive r/r MM " Safety and maximum tolerated dose FPI Q4 2012 Data presented at ASCO 2015 Updated data presented at ASCO 2016 and ASH 2016 Data published in Blood 2017;130(22):2401- 2409 and Am J Hematol 2021 Apr 1;96(4):418- 427 NCT01794520 ■ Safety, objective response rate, Pharmacokinetics, Pharmacodynamics " FPI Q1 2017 Data published Blood Adv 2021 Oct 12;5(19):3748-3759 NCT02899052 Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute; Bcl-2-B-cell lymphoma 2; MM-multiple myeloma; r/r-Relapsed or refractory; ASCO-American Society of Clinical Oncology; ASH-American Society of Hematology ■ Progression-free survival ☐ ■ FPI Q4 2018 NCT03539744 97 97 Oncology#98Venclexta Novel small molecule Bcl-2 selective inhibitor - myelodysplastic syndromes Indication Relapsed or refractory myelodysplastic syndromes (MDS) Treatment-naive myelodysplastic syndromes (MDS) Newly diagnosed higher-risk myelodysplatic syndrome (MDS) Phase/study Phase lb Phase lb Phase III VERONA # of patients Design Primary endpoint Status CT Identifier Cohort 1: N=70 ARM A: Venclexta 400 mg ARM B: Venclexta 800 mg Cohort 2: ARM A: Venclexta plus azacitidine Study expansion: Venclexta or Venclexta plus azacitidine Safety, efficacy, Pharmacokinetics and Pharmacodynamics FPI Q1 2017 Recruitment completed Q1 2022 NCT02966782 N=129 Dose escalation cohort: Venclexta plus azacitidine dose escalation Safety expansion cohort " Safety, Pharmacokinetics, RPTD FPI Q1 2017 Data presented at ASH 2019, ASH 2020 and ASCO 201 BTD granted by FDA July 2021 Recruitment completed Q1 2022 NCT02942290 " " N=500 ARM A: Venclexta plus azacitidine ARM B: Placebo plus azacitidine Complete remission rate and overall survival ■ FPI Q4 2020 NCT04401748 Joint project with AbbVie, in collaboration with The Walter and Eliza Hall Institute Bcl-2-B-cell lymphoma 2; BTD=Breakthrough therapy designation; RPTD=Recommended phase II dose; ASH-American Society of Hematology 98 Roche Oncology#99Polivy (polatuzumab vedotin) ADC targeting CD79b to treat B cell malignancies Indication Phase/study # of patients Design Primary endpoint Status CT Identifier 1L DLBCL Phase III POLARIX N=879 ARM A: Polivy plus R-CHP ARM B: R-CHOP ☐ Progression-free survival FPI Q4 2017 Recruitment completed Q2 2019 Study met primary endpoint Q3 2021 ■ Data presented at ASH 2021 ■Filed in EU, Japan and China Q4 2021 Published in NEJM 2022 Jan 27;386(4):351-363 Approved in EU Q2 2022 NCT03274492 In collaboration with Seagen Inc. DLBCL-diffuse large B cell lymphoma; R-CHP-Rituxan, cyclophosphamide, hydroxydoxorubicin, prednisone; R-CHOP=Rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone; ASH-American Society of Hematology, NEJM-New England Journal of Medicine Roche 99 99 Oncology#100Rozlytrek (entrectinib) CNS-active and selective inhibitor of NTRK/ROS1 Indication Locally advanced or metastatic tumors with ROS1 gene rearrangement Locally advanced or metastatic tumors with NTRK1/2/3 gene rearrangement Pediatric tumors with NTRK 1/2/3, ROS-1 or ALK rearrangement Roche Phase/study # of patients Phase II STARTRK2 N-300 total Single arm with Baskets based on tumor type and genomic alteration status Phase II STARTRK2 N-300 total Single arm with Baskets based on tumor type and genomic alteration status Phase I/lb STARTRK - NG N-80 Single arm with Baskets based on tumor type and genomic alteration status Design ▪ Objective response rate Primary endpoint FPI Q1 2016 Status Data presented at WCLC 2018 ■ Objective response rate FPI Q1 2016 Data presented at ESMO 2018 ■ Maximum tolerated dose and RPTD FPI Q2 2016 Initial data presented at ASCO 2019 ■ Breakthrough Therapy Designation granted by FDA (Q2 2017), PRIME designation granted by EMA (Q1 2018) and Sakigake Designation granted by MHLW (Q4 2017) for NTRK fusion-positive, locally advanced or metastatic solid tumors Filed in US Q4 2018 and EU Q1 2019 ■ Approved in US Q3 2019 and EU Q3 2020 Published in Lancet Oncol. 2020 Feb;21(2):261-271 and 271-282 CT Identifier NCT02568267 NCT02568267 NCT02650401 ALK-Anaplastic lymphoma kinase; CNS-Central Nervous System; MHLW=Ministry of Health, Labor and Welfare; NTRK-neurotrophic receptor tyrosine kinase; PRIME= priority medicines; RPTD=Recommended phase II dose; ROS1-C-ros oncogene 1; WCLC=World Conference on Lung Cancer; ESMO-European Society for Medical Oncology; ASCO-American Society of Clinical Oncology 100 Oncology#101Gavreto (pralsetinib, RG6396) Highly selective RET inhibitor Indication Phase/study # of patients Design " RET+ NSCLC, thyroid cancer and other advanced solid tumors Phase I/II ARROW N=647 Part 1: Gavreto 30-600mg dose escalation Part 2: Gavreto 400mg dose expansion ☐ Primary endpoint Safety and efficacy " Status CT Identifier ☐ Data presented at ASCO (NSCLC) and ESMO (MTC) 2020 ■ Filed in US and EU for RET fusion-positive NSCLC and US for RET-mutant MTC and RET fusion-positive thyroid cancer ▪ Approved in US Q3 2020 in RET fusion-positive NSCLC, in Q4 2020 in RET- mutant MTC and RET fusion-positive thyroid cancer Updated data presented at ASCO 2021 and 2022 Data published in Lancet Oncol 2021 Jul;22(7):959-969 and Lancet Diabetes & Endocrinology Aug 2021;9(8):491-501 ▪ Approved in EU for RET fusion-positive NSCLC Q4 2021 NCT03037385 1L RET fusion-positive, metastatic NSCLC Arm A: Gavreto 400mg Phase III AcceleRET Lung N=250 Arm B: Platinum-based chemotherapy +/- pembrolizumab Progression-free survival Study initiated in Q1 2020 NCT04222972 In collaboration with Blueprint Medicines NSCLC-non-small cell lung cancer; MTC-medullary thyroid cancer; RET=Rearranged during transfection; ASCO=American Society of Clinical Oncology; ESMO-European Society for Medical Oncology Roche 101 Oncology#102Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 3L+ FL, 3L+ DLBCL & other relapsed or refractory NHL 1L DLBCL Relapsed or refractory DLBCL Phase/study # of patients Design Primary endpoint Status Phase I/II N=746 ■ Dose escalation study of Lunsumio as single agent and in combination with Tecentriq Expansion cohorts for r/r FL, r/r DLBCL and SC in r/r NHL " Safety, tolerability, dose/schedule, PK and response rates Data in r/r NHL presented at ASH 2018 and 2019, and in r/r FL at ASH 2020 and ASH 2021 BTD granted by FDA Q2 2020 ■ SC cohort FPI Q2 2021 Filed in EU and rolling submission submitted in US Q4 2021 " Phase Ib/II N=160 Lunsumio plus CHOP Lunsumio plus CHP plus Polivy ■ Lunsumio plus CHP-Polivy vs Rituximab plus CHP-Polivy Safety/tolerability and response " FPI Q1 2019 Data for Lunsumio plus CHOP presented at ASH 2020 ☐ Phase lb N=262 ▪ Lunsumio plus Polivy, randomised cohorts ARM A: Lunsumio SC plus Polivy - ARM B: Rituximab plus Polivy ▪ Safety/tolerability and response FPI Q3 2018 Initial data presented at ASCO and ASH 2021 CT Identifier ☐ Approved in EU Q2 2022 - Filed in US (priority review) Q2 2022 NCT02500407 NCT03677141 NCT03671018 FL-follicular lymphoma; DLBCL-diffuse large B cell lymphoma; r/r-relapsed/refractory; NHL-non-Hodgkin's lymphoma; R=Rituximab; SC-subcutaneous; CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone; CHP-cyclophosphamide, doxorubicin, and prednisone); PK-Pharmacokinetics; BTD=Breakthrough Therapy Designation; ASH-American Society of Hematology; ASCO-American Society of Clinical Oncology 102 Roche Oncology#103Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 1L DLBCL & 2L DLBCL following 1L induction Relapsed or refractory 2L+ FL Phase/study # of patients Design ☐ Phase I Phase lb N=92+80 (cohort C) N=27 Cohort A: Lunsumio monotherapy (after a response to prior systemic chemotherapy) ☐ Lunsumio plus lenalidomide safety run-in for phase III Lunsumio SC plus lenalidomide Cohort B: Lunsumio monotherapy (1L treatment in elderly/frail) Cohort C: Lunsumio SC plus Polivy in 1L elderly/unfit Primary endpoint ■ Safety/tolerability and response Status " CT Identifier FPI Q2 2019 - Cohort B FPI Q3 2019 - Cohort A Initial data presented at ASH 2020 (cohort B) Cohort C: FPI Q1 2021 NCT03677154 ■ Safety/tolerability and response FPI Q3 2020 Initial data presented at ASH 2021 FL-follicular lymphoma; DLBCL-diffuse large B cell lymphoma; r/r-relapsed/refractory; SC=subcutaneous; ASH-American Society of Hematology NCT04246086 Roche 103 Oncology#104Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ FL Relapsed or refractory FL Relapsed or refractory CLL Phase/study # of patients Phase III CELESTIMO Phase Ib/II Phase Ib/II N=400 N=118 ▪ ARM A: Lunsumio plus lenalidomide ▪ ARM B: Rituxan plus lenalidomide ▪ ARM A: Lunsumio plus tiragolumab Design ▪ ARM B: Lunsumio plus tiragolumab plus Tecentriq ■ Dose escalation phase Dose expansion phase N=56 Lunsumio monotherapy (3L+ CLL) ▪ Progression-free survival " Phase Ib: Dose-limiting toxicity Primary endpoint Phase II: Best complete response Status CT Identifier FPI Q4 2021 NCT04712097 FPI Phase lb Q2 2022 NCT05315713 FL=follicular lymphoma; r/r=relapsed/refractory; RPTD=Recommended Phase II Dose; CLL=Chronic lymphocytic leukemia ■ Safety, dose-limiting toxicity and RPTD ■ FPI Q1 2022 104 Roche Oncology#105Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Phase/study # of patients ARM A: Lunsumio plus Polivy ARM B: R + GemOx Design Primary endpoint Status CT Identifier ▪ Progression-free survival FPI Q2 2022 DLBCL-diffuse large B cell lymphoma; SCT=stem cell transplant; R=Rituxan/MabThera; GemOx-Gemcitabin und Oxaliplatin 2L+ SCT ineligible DLBCL Phase III SUNMO N=222 NCT05171647 105 Roche Oncology#106Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody selectively targeting CD20+ B cells Indication Relapsing multiple sclerosis (RMS) Primary progressive multiple sclerosis (PPMS) Phase/study # of patients Design Primary endpoint Status Phase III OPERA I N=821 96-week treatment period: ▪ ARM A: Ocrevus 2x300mg IV followed by 600mg IV every 24 weeks ARM B: Interferon ẞ-1a (Rebif) ▪ Annualized relapse rate at 96 weeks versus Rebif Phase III OPERA II N=835 96-week treatment period: ▪ ARM A: Ocrevus 2x300mg IV followed by 600mg IV every 24 weeks ARM B: Interferon ẞ-1a (Rebif) Annualized relapse rate at 96 weeks versus Rebif " Primary endpoint met Q2 2015, OLE ongoing Primary data presented at ECTRIMS 2015 Phase III ORATORIO N=732 120-week treatment period: " " ARM A: Ocrevus 2x300mg IV every 24 weeks ARM B: Placebo ▪ Updated data presented at AAN and ECTRIMS 2017, AAN and EAN 2018 Data published in NEJM 2017; 376:221-234 Data published on COVID-19 in Mult Scler Relat Disord on Ocrevus treated people with MS, doi.org/10.1016/j.msard.2020.102725 " Sustained disability progression versus placebo by EDSS Primary endpoint met Q3 2015 Primary data presented at ECTRIMS 2015, updated data presented at AAN and ECTRIMS 2017, AAN and EAN 2018 Data published in NEJM 2017; 376:209-220 CT Identifier NCT01247324 ■ Approved in US Q1 2017 and EU Q1 2018 NCT01412333 NCT01194570 IV-intravenous; EDSS-Expanded Disability Status Scale; OLE=Open label extension; ECTRIMS-European Committee for Treatment and Research in Multiple Sclerosis; AAN=Annual Meeting of the American Academy of Neurology; 106 EAN-European Academy of Neurology; NEJM-New England Journal of Medicine Roche Neuroscience#107Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody selectively targeting CD20+ B cells Indication Relapsing and primary progressive multiple sclerosis (RMS & PPMS) Primary progressive multiple sclerosis (PPMS) Phase/study # of patients Design Phase Illb ENSEMBLE PLUS Phase IIIb ORATORIO-HAND N=1,225 • • Substudy of ongoing phase IIIb, open-label, single-arm ENSEMBLE study Shorter two-hour infusion time 120-week treatment period: ☐ ARM A: Ocrevus 600mg IV q24w ☐ ARM B: Placebo N - 1000 Primary endpoint Status . Safety, measured by the proportion of patients with IRRs following the first randomised 600 mg infusion (frequency/severity assessed during and 24- hours post infusion) • Filed in US and EU Q1 2020 • Approved in EU Q2 2020 and US Q4 2020 • Data published Neurol, Neuroimmunol and Neuroinflamm Sept 2020; 7(5), e807 Time to upper limb disability progression confirmed for at least 12 weeks FPI Q3 2019 CT Identifier IV-intravenous; IRR=Infusion Related Reaction NCT03085810 NCT04035005 107 Roche Neuroscience#108Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody selectively targeting CD20+ B cells Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) PPMS & RMS Roche Phase/study # of patients Design Primary endpoint Phase IIIb GAVOTTE N-699 120-week treatment period: ▪ ARM A: Ocrevus 600mg IV every 24 weeks ARM B: Ocrevus 1200mg if body weight <75kg or 1800mg if body weight > or equal to 75kg every 24 weeks ▪ Superiority of Ocrevus higher dose versus approved dose on CCDP " Phase Illb MUSETTE N-786 120-week treatment period: ARM A: Ocrevus 600mg IV every 24 weeks ARM B: Ocrevus 1200mg if body weight <75kg or 1800mg if body weight > or equal to 75kg every 24 weeks " ARM A: Ocrevus IV Phase III Ocarina II¹ ARM B: Ocrevus SC N-232 Superiority of Ocrevus higher dose versus approved dose on CCDP Serum Ocrevus area under the concentration-time curve (AUCW1-12) at week 12 Status CT Identifier FPI Q4 2020 NCT04548999 1SC with Halozyme's rHuPH20/ Halozyme's human hyaluronidase CCDP-composite confirmed disability progression; IV-intravenous; SC-Subcutaneous " FPI Q4 2020 ■ Recruitment completed Q4 2021 NCT04544436 FPI Q2 2022 NCT05232825 108 Neuroscience#109Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Phase/study # of patients Design Primary endpoint Status Phase II/III FIREFISH N=21 (Part 1), 41 (Part 2) Open-label study in infants with type 1 SMA - Part 1 (dose-finding): At least 4 weeks Part 2 (confirmatory): 24 months ■ Safety, tolerability, PK/PD and efficacy 12-month data from Part 1 presented at AAN, CureSMA and EAN 2019; 16-month data presented at WMS 2019 ▪ Study met primary endpoint in part 2 Q1 2020 Part 2 1-year data presented at AAN 2020, part 12- year data at WMS 2020 ■ Part 1 data published in NEJM 2021;384:915-923 ▪ Part 2 2-year data presented at AAN 2021 ▪ Part 2 1-year data published in NEJM 2021;385:427- 435 ■ 3-year data presented at EPNS 2022 Spinal muscular atrophy (SMA) Phase II/III SUNFISH N=51 (Part 1), 180 (Part 2) Randomized, double-blind, placebo-controlled study in adult and pediatric patients with type 2 or type 3 SMA: ☐ " · Part 1 (dose-finding): At least 12 weeks · Part 2 (confirmatory): 24 months Safety, tolerability, PK/PD and efficacy ▪ Recruitment completed for part 2 Q3 2018 ▪ 12-month data from Part 1 presented at AAN, CureSMA and EAN 2019; 16-month data presented at WMS 2019 ▪ Study met primary endpoint in part 2 Q4 2019 · Part 2 1-year data presented at SMA Europe 2020, 2-year data at MDA 2021 and 3-year data at MDA 2022 ▪ Part 2 data 1-year published in Lancet Neurology, Dec 2021 Phase II JEWELFISH N=174 * Open-label single arm study in adult and pediatric patients with previously treated SMA type 1, 2 and 3 ■ Safety, tolerability, PK/PD "FPI Q1 2017 ' Data presented at WMS 2017, AAN 2018, WMS 2018, CureSMA 2019, WMS 2019, CureSMA 2020 and 2021 ▪ Recruitment completed Q1 2020 Orphan drug designation granted by FDA Q1 2017 and EU Q1 2019, PRIME designation in Q4 2018 CT Identifier NCT02913482 In collaboration with PTC Therapeutics and SMA Foundation ■ Approved in US Q3 2020 and EU Q1 2021 NCT02908685 NCT03032172 SMA-Spinal muscular atrophy; SMN=survival motor neuron; PK/PD-Pharmacokinetics/Pharmacodynamics; PRIME-priority medicines; AAN-American Academy of Neurology; WMS-World Muscle Society; EAN-European Academy of Neurology; NEJM-New England Journal of Medicine; MDA-Muscular Dystrophy Association; CureSMA=Annual SMA Conference; EPNS-European Paediatric Neurology Society 109 Roche Neuroscience#110Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Phase/study Phase II RAINBOWFISH Spinal muscular atrophy (SMA) Phase II/III MANATEE Roche # of patients Design Primary endpoint Status N=25 Open-label, single-arm, multicenter study in infants aged from birth to 6 weeks who have been genetically diagnosed with Spinal muscular atrophy but are not yet presenting with symptoms ▪ Proportion of participants with two copies of the SMN2 gene (excluding the known SMN2 gene modifier mutation c.859G>C) and baseline CMAP>=1.5 millivolt who are sitting without support ■ FPI Q3 2019 ▪ Recruitment completed Q1 2022 ▪ Initial data presented at CureSMA, WMS 2021 and MDA 2022 ARM A: N=180 Part 1: GYM329 plus Evrysdi for 24 weeks, followed by GYM329 plus Evrysdi for 72 weeks Part 2: GYM329 plus Evrysdi for 72 weeks ARM B: Placebo plus Evrysdi comparator Change from baseline in revised hammersmith scale (RHS) score after week 72 of treatment • Safety, PK/PD and muscle biomarkers FPI Part 1 Q2 2022 Orphan Drug Designation granted by FDA in Q4 2021 for GYM329 ☐ Filed in US and EU Q4 2021 ▪ Approved in US Q2 2022 CT Identifier In collaboration with PTC Therapeutics and SMA Foundation NCT03779334 NCT05115110 SMN=survival motor neuron; CMAP=compound muscle action potential; PK/PD-Pharmacokinetics/Pharmacodynamics; WMS-World Muscle Society; CureSMA=Annual SMA Conference; MDA-Muscular Dystrophy Association 110 Neuroscience#111Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Neuromyelitis optica spectrum disorder (NMOSD) Phase/study # of patients Design Primary endpoint Enspryng monotherapy: Phase III SAkuraStar N=95 . • ARM A: Enspryng 120mg SC monthly • ARM B: Placebo SC monthly •Efficacy (time to first relapse), safety and PK/PD Primary endpoint met Q4 2018 " Data presented at ECTRIMS 2019 ■ Published in Lancet Neurology 2020; 19(5): 402-412 Status CT Identifier NCT02073279 Phase III SAkuraSky N=83 Add-on therapy of Enspryng: • ARM A: Enspryng 120mg SC monthly Roche • ARM B: Placebo SC monthly Both arms on top of baseline therapies: azathioprine, mycophenolate mofetil or oral corticosteroids ■ Efficacy (time to first relapse), safety and PK/PD ☐ FPI Q3 2017 Primary endpoint met Q3 2018 ■ Data presented at ECTRIMS 2018 and AAN 2019 Published in NEJM 2019; 381:2114-2124 BTD granted by FDA Q4 2018 Filed in EU Q3 2019; US acceptance of filing Q4 2019 " Approved in US Q3 2020 and EU Q2 2021 NCT02028884 *Trials managed by Chugai (Roche opted-in) BTD=Breakthrough therapy designation; PK/PD-Pharmacokinetics/Pharmacodynamics; SC-Subcutaneous; ECTRIMS-European Committee for Treatment and Research in Multiple Sclerosis; AAN-American Academy of Neurology; NEJM New England Journal of Medicine 111 Neuroscience#112Roche Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Generalised myasthenia gravis (MG) Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) Phase/study # of patients Phase III Luminesce N=240 • ARM A: Enspryng plus standard of care Design Primary endpoint Status CT Identifier • ARM B: Placebo plus standard of care ■ Mean change from baseline in total MG-ADL score at week 24 in AChR+ population Orphan Drug Designation granted in US Q1 2021 FPI Q4 2021 NCT04963270 Phase III METEOROID N=152 ⚫ARM A: Enspryng at weeks 0, 2, 4 (loading doses) and maintenance doses q4w ⚫ARM B: Placebo ■ Time from randomization to the first occurrence of a MOGAD relapse ■ FPI expected Q3 2022 Orphan Drug Designation granted by FDA in Q4 2021 In collaboration with Chugai MG-ADL= Myasthenia Gravis Activities of Daily Living; AChR-Acetylcholine receptor; MOGAD-Myelin Oligodendrocyte Glycoprotein Antibody Disease NCT05271409 112 Neuroscience#113Gazyva (obinutuzumab) Immunology development program Indication Lupus nephritis Membranous nephropathy Roche Phase/study # of patients Design Phase II NOBILITY N=126 ARM A: Gazyva 1000mg IV plus mycophenolate mofetil/mycophenolic acid - ARM B: Placebo IV plus mycophenolate mofetil/ mycophenolic acid ☐ Phase III REGENCY N=252 ARM A: Gazyva 1000mg IV (6 doses through Week 52) plus mycophenolate mofetil ARM B: Gazyva 1000 mg IV (5 doses through Week 52) plus mycophenolate mofetil ARM C: Placebo IV plus mycophenolate mofetil Phase III MAJESTY N=140 ARM A: Gazyva 1000mg IV dosed at baseline and weeks 0, 2, 24, and 26 on top of renin- angiotensin inhibitors ARM B: Tacrolimus treatment for 12 months Primary endpoint Status Percentage of participants who achieve complete renal response (CRR) ▪ Recruitment completed Q4 2017 Primary endpoint met Q2 2019 ■ BTD granted by the FDA Q3 2019 Data presented at ASN and ACR 2019 ■ Published in Ann Rheum Dis 2022 Jan;81(1):100- 107 CT Identifier NCT02550652 Percentage of participants who achieve complete renal response (CRR) FPI Q3 2020 Percentage of patients who achieve complete remission at week 104 ■ FPI Q2 2021 NCT04221477 In collaboration with Biogen BTD=Breakthrough therapy designation; IV=Intravenous; ASN=American Society of Nephrology; ACR=American College of Rheumatology NCT04629248 113 Immunology#114Gazyva (obinutuzumab) Immunology development program Indication Phase/study # of patients Design Primary endpoint Status CT Identifier In collaboration with Biogen IV=Intravenous • Systemic lupus erythematosus (SLE) Phase III ALLEGORY N=200 . . ARM A: Gazyva 1000mg IV on Day 1 and Weeks 2, 24 and 26. ARM B: Placebo IV Percentage of participants who achieve Systemic Lupus Erythematosus Responder Index (SRI) at week 52 • FPI Q4 2021 NCT04963296 Roche 114 Immunology#115Actemra/RoActemra (tocilizumab, RG-1569) Interleukin 6 receptor inhibitor Indication Phase/study # of patients Design Phase III COVACTA¹ N=450 ARM A: Actemra plus standard of care ◉ ARM B: Placebo plus standard of care Adult hospitalised with severe COVID-19 pneumonia Phase III REMDACTA² ARM A: Remdesivir plus Actemra ARM B: Remdesivir plus placebo N=650 Primary endpoint ◉ - Clinical status assessed using 7-Category Ordinal Scale (Day 28) FPI Q1 2020 Recruitment completed Q2 2020 Primary endpoint not met Q3 2020 Status ☐ Published in NEJM 2021; 384:1503-1516 Time to hospital discharge or ready for discharge ■ FPI Q2 2020 Recruitment completed Q1 2021 Primary endpoint not met Q1 2021 Published in Intensive Care Med 2021 doi: 10.1007/s00134-021-06507-x CT Identifier NCT04320615 Filed in EU Q3 2021 Approved in EU Q4 2021 In collaboration with US Biomedical Advanced Research and Development Authority (BARDA); 2In collaboration with Gilead Sciences, Inc. NEJM-New England Journal of Medicine NCT04409262 115 Roche Immunology#116Actemra/RoActemra (tocilizumab, RG-1569) Interleukin 6 receptor inhibitor Indication Phase/study # of patients Design Primary endpoint Status " CT Identifier ☐ " ◉ ◉ Adult hospitalised with severe COVID-19 pneumonia Phase II MARIPOSA N=100 ARM A: 8 mg/kg Actemra plus standard of care ARM B: 4mg/kg Actemra plus standard of care Phase III EMPACTA N=379 Conducted in sites known to provide critical care to underserved and minority populations that often do not have access to clinical trials ARM A: Actemra plus standard of care ARM B: Placebo plus standard of care Pharmacodynamics and pharmacokinetics FPI Q2 2020 Recruitment completed Q2 2020 Published in Open Forum Infect Dis 2021 Dec 4;9(1) NEJM-New England Journal of Medicine NCT04363736 Roche Cumulative proportion of participants requiring mechanical ventilation by day 28 ■ FPI Q2 2020 Primary endpoint met Q3 2020 Published in NEJM 2021 Jan 7;384(1):20-30 Filed in EU Q3 2021 ☐ ▪ Approved in EU Q4 2021 NCT04372186 116 Immunology#117Xolair Humanized monoclonal antibody that selectively binds to IgE Indication Food allergy Phase/study Phase III OUTMATCH¹ # of patients N=225 • Xolair by SC injection either q2w or q4w for 16 to 20 weeks Design Primary endpoint • Number of participants who successfully consume ≥600mg of peanut protein without dose-limiting symptoms Status • ⚫ FPI Q3 2019 CT Identifier In collaboration with Novartis; 1 Sponsor of the study is the National Institute of Allergy and Infectious Diseases (NIAID) IgE-Immunoglobulin E; SC-Subcutaneous NCT03881696 117 Roche Immunology#118Lunsumio (mosunetuzumab, CD20 x CD3, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Systemic lupus erythematosus (SLE) Phase/study # of patients ARM A: Lunsumio SC on either Day 1 or on Days 1 and 8 ARM B: Fractionated (divided) dose of Lunsumio SC on Days 1 and 8 Design - Safety Primary endpoint Status CT Identifier SC=subcutaneous FPI January 2022 Phase I N=50 NCT05155345 118 Roche Immunology#119Susvimo (PDS) First eye implant to achieve sustained delivery of a biologic medicine Indication Wet age-related macular degeneration (wAMD) Phase/study # of patients Design Phase III Archway N=418 ARM A: Port delivery system with ranibizumab q24w ■ ARM B: Intravitreal ranibizumab q4w Roche Phase II+III extension Portal N=1,000 Patients from LADDER or Archway will receive refills of 100mg/mL ranibizumab q24w (patients without the PDS will receive the PDS and subsequent refills) Phase Illb Velodrome N=442 - ARM A: Port delivery system with ranibizumab 936w ▪ ARM B: Port delivery system with ranibizumab q24w Change in BCVA from baseline at the average of ▪ Safety and long term efficacy week 36 and week 40 Primary endpoint FPI Q3 2018 FPI Q3 2018 ■ Change in BCVA from baseline averaged over weeks 68 and 72 FPI Q3 2021 Status CT Identifier Recruitment completed Q2 2019 ▪ Study met primary endpoint Q2 2020 Primary endpoint data presented at ASRS 2020, 44/48 week data at Angiogenesis 2021 and 2- year data at Angiogenesis 2022 Filed in US (PRIME) and EU Q2 2021 ▪ Approved in US Q4 2021 NCT03677934 NCT03683251 NCT04657289 119 BCVA=best corrected visual acuity; wAMD-wet age-related macular degeneration; ASRS-American Society of Retinal Specialists; PDS-Port Delivery System with ranibizumab; PRIME=Priority review Ophthalmology#120Susvimo (PDS) First eye implant to achieve sustained delivery of a biologic medicine Indication Diabetic macular edema (DME) Diabetic retinopathy (DR) without center-involved diabetic macular edema (DME) Phase/study # of patients Design Primary endpoint Status CT Identifier Phase III Pagoda N=545 " ARM A: Port delivery system with ranibizumab q24w ARM B: Intravitreal ranibizumab q4w Phase III Pavilion N=160 Roche ■ Arm A: Intravitreal ranibizumab (X2) followed by PDS implant (refill q36w) Arm B: Q4w comprehensive clinical monitoring until participants receive PDS (refill q36w) Change in BCVA from baseline at the average of week 48 and week 52 Percentage of participants with a ≥2-step improvement from baseline on the ETDRS-DRSS at Week 52 ◉ FPI Q3 2019 Recruitment completed Q2 2021 NCT04108156 ◉ FPI Q3 2020 Recruitment completed Q3 2021 BCVA=best corrected visual acuity; ETDRS-Early Treatment Diabetic Retinopathy Study; DRSS=Diabetic Retinopathy Severity Scale; PDS-Port Delivery System with ranibizumab NCT04503551 120 Ophthalmology#121Vabysmo (faricimab) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Indication Phase/study # of patients Design Phase III YOSEMITE N=940 ☐ ARM A: Faricimab q8w - ARM B: Faricimab PTI up to q16w ARM C: Aflibercept, q8w Center-involving diabetic macular edema (CI-DME) ■ ARM A: Faricimab q8w Phase III RHINE N=951 ■ ARM B: Faricimab PTI up to q16w ARM C: Aflibercept, q8w Primary endpoint Status ▪ Change from baseline in BCVA at 1 year FPI Q3 2018 Recruitment completed Q3 2019 Study met primary endpoint Q4 2020 Data presented at Angiogenesis 2021 Change from baseline in BCVA at 1 year ■ FPI Q4 2018 Recruitment completed Q3 2019 Study met primary endpoint Q4 2020 Data presented at Angiogenesis 2021 ■ Filed in US and EU Q2 2021 Published in the Lancet 2022 Feb 19;399(10326):741-755. 2-year data presented at Angiogenesis 2022 " Approved in US Q1 2022 CT Identifier NCT03622580 Ang-2-Angiopoietin-2; VEGF-Vascular endothelial growth factor; PTI=Personalized Treatment Interval; BCVA-best corrected visual acuity NCT03622593 121 Roche Ophthalmology#122Vabysmo (faricimab) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Indication Phase/study # of patients Design Primary endpoint Status " " Phase III TENAYA N=671 ARM A: Faricimab 6.0mg q16w flexible after 4 IDs ARM B: Aflibercept 2.0mg q8w after 3 IDs Change from baseline in BCVA week 40, 44 & 48 Wet age related macular degeneration (wAMD) Phase III LUCERNE N=658 ARM A: Faricimab 6.0mg q16w flexible after 4 IDs ARM B: Aflibercept 2.0mg q8w after 3 IDs " ■ Change from baseline in BCVA week 40, 44 & 48 FPI Q1 2019 Recruitment completed Q4 2019 Study met primary endpoint Q1 2021 Data presented at Angiogenesis 2021 ■ ◉ FPI Q1 2019 Recruitment completed Q4 2019 Study met primary endpoint Q1 2021 Data presented at Angiogenesis 2021 Filed in US and EU Q2 2021 ▪ Published in Lancet 2022 Feb 19;399(10326):729-740 Approved in US Q1 2022 ■ 2-year data presented at ASRS 2022 CT Identifier NCT03823287 BCVA-best corrected visual acuity; Ang-2-Angiopoietin-2; VEGF-Vascular endothelial growth factor; IDs-initiating doses; ASRS-American Society of Retina Specialists NCT03823300 Roche 122 Ophthalmology#123Vabysmo (faricimab) Bispecific antibody to simultaneously bind Ang-2 and VEGF-A Roche Indication Macular edema (ME) secondary to branch retinal vein occlusion (RVO) Macular edema (ME) secondary to central retinal vein occlusion (RVO) Phase/study # of patients Design Primary endpoint Status CT Identifier " ARM A: Faricimab, q4w/PTI ARM B: Aflibercept, q4w Phase III BALATON N=570 Change from baseline in BCVA at week 24 " FPI Q1 2021 Recruitment completed Q1 2022 NCT04740905 ARM A: Faricimab, q4w/PTI ARM B: Aflibercept, q4w Phase III COMINO N=750 " ☐ ■ Change from baseline in BCVA at week 24 FPI Q1 2021 Recruitment completed Q1 2022 PTI=Personalized Treatment Interval; BCVA=best corrected visual acuity; Ang-2-Angiopoietin-2; VEGF-Vascular endothelial growth factor NCT04740931 123 Ophthalmology#124Xofluza (baloxavir marboxil, RG6152, S-033188) Small molecule, novel CAP-dependent endonuclease inhibitor Indication Influenza Roche Phase/study # of patients Design Phase III miniSTONE 1 (0-1 year old) N=30 Xofluza on Day 1 (based on body weight and age) in healthy pediatric patients from birth to <1 year with influenza-like symptoms Phase III miniSTONE 2 (1- <12 years old) N=176 Healthy pediatric patients 1 to <12 years of age with influenza-like symptoms ARM A: Xofluza ARM B: Tamiflu Phase IIIb CENTERSTONE N=3,160 Reduction of direct transmission of influenza from otherwise healthy patients to household contacts ARM A: Xofluza ARM B: Placebo Primary endpoint Status CT Identifier ■ Safety Safety • ⚫ FPI Q1 2019 • Primary endpoint met Q2 2019 . Data presented at OPTIONS X 2019 • Filed in US Q1 2020 • In collaboration with Shionogi & Co., Ltd. CAP=Catabolite Activating Protein NCT03653364 • . Data published in Pediatric Infectious Disease 2020 Aug;39(8):700-705 Not approved in the US, determining path forward with the FDA Filed in EU Q4 2021 NCT03629184 ■ Percentage of household contacts who are PCR- positive for influenza by day 5 post randomization of index patients ■ FPI Q4 2019 NCT03969212 124 Infectious Diseases#125Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (PRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#126Ipatasertib (RG7440, GDC-0068) Highly selective small molecule inhibitor of Akt Indication Phase/study # of patients ▪ ARM A: Ipatasertib plus abiraterone Design ☐ ▪ ARM B: Placebo plus abiraterone 1L castration-resistant prostate cancer (CRPC) Phase III IPATential150 N=1,100 Primary endpoint Status " rPFS in patients with PTEN loss tumors and overall population FPI Q2 2017 Recruitment completed Q1 2019 ▪ Study met co-primary endpoint in rPFS in patients with PTEN loss tumors Q2 2020 Data presented at ESMO 2020 and interim OS at ASCO 2022 ■ Published in Lancet 2021; 398:131-142 CT Identifier NCT03072238 Akt-Protein Kinase B; PTEN=Phosphatase and Tensin homolog; rPFS-Radiographic progression-free survival; ESMO-European Society for Medical Oncology 126 Roche Oncology#127Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication 1L NSCLC PD-L1 TPS>50% Phase/study # of patients Phase III SKYSCRAPER-01 N=500-560 ARM A: Tiragolumab plus Tecentriq Design ARM B: Placebo plus Tecentriq Primary endpoint ▪ Overall survival and progression-free survival Stage III unresectable 1L NSCLC Phase III SKYSCRAPER-03 N=800 ARM A: Tiragolumab plus Tecentriq for up to 12 months ARM B: Durvalumab for up to 12 months ■ Progression-free survival Status FPI Q1 2020 Recruitment completed Q3 2021 FPI Q3 2020 Study did not meet its co-primary endpoint of PFS Q2 2022 CT Identifier NCT04294810 NCT04513925 NSCLC=Non-small cell lung cancer; ES-SCLC-Extensive stage small cell lung cancer; PD-L1-Programmed cell death-ligand 1; TPS-Tumor Proportion Score; PFS-Progression-free survival 127 Roche Oncology#128Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Metastatic and/or recurrent PD-L1+ cervical cancer (CC) Neoadjuvant and adjuvant NSCLC Phase/study # of patients Phase II SKYSCRAPER-04 N=172 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq Design ■ Objective response rate Primary endpoint FPI Q2 2020 Status CT Identifier NCT04300647 NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1 Phase II SKYSCRAPER-05 N=82 1L non-squamous NSCLC Phase II/III SKYSCRAPER-06 N=500 " ■ ARM A: (PD-L1 high) neoadjuvant tiragolumab plus Tecentriq followed by adjuvant tiragolumab plus Tecentriq or adjuvant chemotherapy ■ ARM B: (PD-L1 all-comers) neoadjuvant tiragolumab plus Tecentriq plus chemo followed by adjuvant tiragolumab plus Tecentriq ■ Pathologic complete response, major pathological response and safety " FPI Q2 2021 " ARM A: Tiragolumab plus Tecentriq plus pemetrexed plus chemo followed by maintenance tiragolumab plus Tecentriq plus pemetrexed ARM B: Placebo plus pembrolizumab plus pemetrexed plus chemo followed by maintenance placebo plus pembrolizumab plus pemetrexed ■ Objective response rate, progression-free survival and overall survival ☐ FPI Q4 2020 NCT04832854 NCT04619797 Roche 128 Oncology#129Roche Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Phase/study # of patients Design Locally advanced esophageal cancer (EC) Phase III SKYSCRAPER-07 N=750 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq plus placebo ARM C: Placebo plus placebo " 1L esophageal cancer (EC) Phase III SKYSCRAPER-08 N=500 ARM A: Tiragolumab plus Tecentriq plus cisplatin and paclitaxel ARM B: Placebo plus placebo plus cisplatin and paclitaxel 1L recurrent/metastatic PD-L1 positive squamous cell head and neck carcinoma (SCCHN) Phase II SKYSCRAPER-09 N=120 ARM A: Tiragolumab plus Tecentriq ARM B: Tecentriq plus placebo ▪ Progression-free survival (A vs C) ◉ Overall survival and progression-free survival ■ Objective response rate Primary endpoint ■ Overall survival (A vs C, hierarchical, B vs C hierarchical) FPI Q3 2020 ■ FPI Q1 2021 Status CT Identifier NCT04543617 NSCLC-Non-small cell lung cancer; PD-L1-Programmed cell death-ligand 1 " FPI Q4 2020 Recruitment completed Q4 2021 NCT04540211 ■ Recruitment completed Q2 2022 NCT04665843 129 Oncology#130Tiragolumab (anti-TIGIT, RG6058, MTIG7192A) Monoclonal antibody targeting the immune checkpoint inhibitor TIGIT Indication Solid tumors NSCLC Roche Relapsed or refractory multiple myeloma (MM) or r/r B-cell NHL Phase/study # of patients Phase I N=540 " Phase la: Dose escalation and expansion of tiragolumab ■ Phase Ib: Dose escalation and expansion of tiragolumab in combination with Tecentriq and/or other anti-cancer therapies Phase II CITYSCAPE N=135 ARM A: Tecentriq plus tiragolumab ARM B: Tecentriq monotherapy Phase I N=52 Phase la: Tiragolumab monotherapy Phase Ib: Tiragolumab plus daratumumab (r/r MM) or rituximab (r/r NHL) " Design Primary endpoint Status CT Identifier Safety, tolerability, PK variability and preliminary efficacy " FPI Q2 2016 Data presented at AACR 2020 NCT02794571 Overall response rate and progression-free survival FPI Q3 2018 Recruitment completed Q2 2019 Data presented at ASCO 2020 and WCLC and ESMO IO 2021 OBTD granted by FDA Q4 2020 Safety, tolerability, PK/PD and preliminary efficacy ■ FPI Q2 2019 NCT03563716 NCT04045028 BTD=Breakthrough therapy designation; MM-Multiple myeloma; NSCLC=Non-small cell lung cancer; r/r-Relapsed refractory; NHL-Non-Hodgkin's lymphoma; PK-Pharmacokinetics; PD-Pharmacodynamics; ASCO=American Society of Clinical Oncology; AACR-American Association for Cancer Research; WCLC=World Conference on Lung Cancer; ESMO IO-European Society for Medical Oncology - Immuno-Oncology 130 Oncology#131Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory Non-Hodgkin's lymphoma (NHL) Roche Phase/study # of patients Design Primary endpoint Status Phase I N=700 Cohort 1: Single-agent dose escalation study ■ Initial dose escalation ☐ Expansion cohort in r/r DLBCL Expansion cohort in r/r FL All patients will receive pretreatment with a single dose of Gazyva (1000mg) Cohort 2: Glofitamab plus Gazyva (i.e. continuous treatment with Gazyva) Efficacy, safety, tolerability and pharmacokinetics FPI Q1 2017 Data presented at ASH 2018, ICML and ASH 2019; EHA and ASH 2020; ASCO, EHA, ICML and ASH 2021; ASCO and EHA 2022 Data published online March 2021 J Clin Oncology 39:18:1959-1970 Phase Ib N=140 Dose escalation and expansion ARM A: Glofitamab plus Tecentriq ARM B: Glofitamab plus Polivy Glofitamab SC Phase I N=18-36 ■ Part 1 dose escalation Safety Safety ☐ Arm A: FPI Q2 2018 " FPI Q3 2021 " Data presented at ASH 2019 and ASH 2021 Arm B: FPI Q4 2020 ☐ Filed in EU April 2022 NCT03075696 CT Identifier NCT03533283 ISRCTN17975931 DLBCL-diffuse large B cell lymphoma; FL=Follicular lymphoma; r/r-Relapsed or refractory; SC=subcutenous; ASCO-American Society of Clinical Oncology; ASH-American Society of Hematology; EHA-European Hematology Association; ICML-International Conference on Malignant Lymphoma 131 Oncology#132Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Non-Hodgkin's lymphoma (NHL) 2L+ SCT-ineligible DLBCL Roche Phase/study # of patients Design Phase lb Part I: 15-60 Part II: ~66-104 ■ Part I: Dose-finding for the combination of glofitamab plus G/R-CHOP in r/r indolent NHL Part II: Dose expansion glofitamab plus G/R-CHOP or R-CHOP in 1L DLBCL Part III: Glofitamab plus R-CHP plus Polivy Phase III STARGLO N=270 ARM A: Glofitamab plus gemcitabine and oxaliplatin, followed by up to 4 cycles of glofitamab monotherapy ARM B: Rituxan in combination with gemcitabine and oxaliplatin A single dose of Gazyva will be administered 7 days prior to the first dose of glofitamab Primary endpoint Status CT Identifier Safety ☐ Part I: FPI Q1 2018 Part II: FPI Q1 2021 Data presented at ASH 2021 NCT03467373 Overall survival " FPI Q1 2021 NCT04408638 DLBCL-diffuse large B cell lymphoma; SCT=stem cell transplant; CHOP-cyclophosphamide, doxorubicin, vincristine and prednisone; R=Rituxan/MabThera; G-Gazyva; NHL-Non-Hodgkin's lymphoma; r/r-Relapsed or refractory ASH-American Society of Hematology 132 Oncology#133Glofitamab (CD20-TCB, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Phase/study # of patients Design ■ 1L ctDNA high risk DLBCL Phase II N=40 Glofitamab plus R-CHOP (glofitamab is introduced as a consolidation to R-CHOP at cycle 3-8 in patients ctDNA+ at cycle 2) " EOT PET-CR Primary endpoint Status CT Identifier FPI Q1 2022 NCT04980222 ctDNA-circulating tumor DNA; DLBCL-diffuse large B cell lymphoma; R-CHOP=Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone; PET=positron emission tomography; EOT PET-CR-End of treatment PET- complete response rate 133 Roche Oncology#134Inavolisib (RG6114, GDC-0077) A potent, orally available, and selective PI3Ka inhibitor Indication PIK3CA-mutant HR+ metastatic breast cancer (mBC) PIK3CA mutant solid tumors and metastatic ER+ HER2-neg breast cancer Roche Phase/study # of patients Design Phase III INAVO120 N=400 ARM A: Inavolisib plus palbociclib plus fulvestrant ARM B: Placebo plus palbociclib plus fulvestrant Phase I N=256 Monotherapy and in combination with standard of care (letrozole; letrozole plus palbociclib; fulvestrant) • Stage 1: Dose escalation • Stage 2: Dose expansion ▪ Progression-free survival Primary endpoint Status CT Identifier FPI Q1 2020 NCT04191499 Safety, tolerability and pharmacokinetics • FPI Q4 2016 • Preclinical/molecule discovery data presented at AACR 2017 • Data presented at SABCS 2019, 2020 and 2021 NCT03006172 ER=Estrogen receptor; HR=Hormon receptor; HER2=Human Epidermal growth factor Receptor 2; PI3K=Phosphoinositide 3-Kinase; AACR=American Association for Cancer Research; SABCS-San Antonio Breast Cancer Symposium 134 Oncology#135Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication ER+ HER2-neg metastatic breast cancer (mBC) ER+ HER2-neg Stage I-III operable breast cancer (BC) Neoadjuvant ER+ breast cancer (BC) Phase/study # of patients Design Primary endpoint Status CT Identifier Phase I Phase I N=181 ■ Dose escalation and expansion at RPTD ■ Giredestrant monotherapy and in combination with palbociclib and/or LHRH agonist N=75 ■ Open-label, pre-operative administration Dose escalation ■ Safety " ■ Safety, tolerability and PK/PD FPI Q4 2017 FPI Q3 2019 ☐ Data presented at SABCS 2019, ASCO 2020, ASCO 2021 and SABCS 2021 ☐ Data presented at ASCO 2021 NCT03332797 NCT03916744 Roche Phase II coopERA Breast Cancer N=221 ARM A: Giredestrant followed by giredestrant plus palbociclib . • ARM B: Anastrazole followed by anastrazole plus palbociclib ■ Safety, tolerability and PK/PD FPI Q3 2020 Data presented at ESMO and SABCS 2021; ASCO 2022 NCT04436744 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor; RPTD=Recommended phase II dose; LHRH=Luteinizing hormone-releasing hormone; PK/PD-Pharmacokinetics/Pharmacodynamics; SABCS=San Antonio Breast Cancer Symposium; ASCO-American Society of Clinical Oncology 135 Oncology#136Giredestrant (SERD (3),RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication 2L/3L ER+/HER2-negative metastatic breast cancer (mBC) 1L ER+ metastatic breast cancer (mBC) Adjuvant ER+ breast cancer (BC) Phase/study # of patients Design Phase II aceLERA Breast Cancer N=303 ARM A: Giredestrant monotherapy ARM B: Endocrine monotherapy (fulvestrant or aromatase inhibitor) Phase III persevERA Breast Cancer N=978 ARM A: Giredestrant plus palbociclib ARM B: Letrozole plus palbociclib Phase III lidERA Breast Cancer N=4,100 ARM A: Giredestrant monotherapy ARM B: Tamoxifen or aromatase inhibitor ■ Progression-free survival Primary endpoint ■ FPI Q4 2020 Recruitment completed Q4 2021 Status ▪ Study did not meet its primary endpoint Q2 2022 CT Identifier NCT04576455 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor ■ Progression-free survival ■ Invasive disease-free survival ☐ ⚫ FPI Q4 2020 NCT04546009 " FPI Q3 2021 NCT04961996 136 Roche Oncology#137Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication 1L ER+/HER2-positive breast cancer (BC) Phase/study # of patients Induction Phesgo plus taxane followed by maintenance with either: ARM A: Giredestrant plus Phesgo Design " ARM B: Phesgo Primary endpoint Status CT Identifier ■ Progression-free survival FPI Q2 2022 Phase III heredERA N=812 NCT05296798 ER-Estrogen receptor; HER2-Human Epidermal growth factor Receptor; Phesgo=FDC of Perjeta and Herceptin for SC administration; 137 Roche Oncology#138zinpentraxin alfa (PRM-151, RG6354) Recombinant human innate immunity protein pentraxin-2 Indication Phase/study # of patients Phase II Idiopathic pulmonary fibrosis (IPF) Phase III STARSCAPE N=658 Myelofibrosis Phase II Design Primary endpoint ☐ N=117 Randomized, double-blind, placebo-controlled trial: 4-week screening period, 24-week randomized treatment period, 4-week follow-up visit (week 28) Zinpentraxin alfa at days 1, 3 and 5, then every 4 weeks vs placebo ▪ Least-squares mean change in FVC percentage of predicted value from baseline to week 28 • Study met primary endpoint • Data published in JAMA 2018;319(22):2299- Status CT Identifier 2307 and Lancet Respir Med 2019 Aug;7(8):657- 664 NCT02550873 " • N=125 Randomized, double-blind, placebo-controlled Multiple dose study of zinpentraxin alfa trial: 4-week screening period, 52-week randomized treatment period ■ Zinpentraxin alfa at days 1, 3 and 5, then every 4 weeks vs placebo •Absolute change from baseline to week 52 in FVC " FPI Q1 2021 NCT04552899 • Bone marrow response rate Study completed Q1 2021 NCT01981850 FVC-Forced vital capacity JAMA Journal of the American Medical Association 138 Roche Immunology#139Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Paroxysmal nocturnal hemoglobinuria (PNH) Roche Paroxysmal nocturnal hemoglobinuria (PNH) patients switching from a C5 inhibitor Phase/study # of patients Design Primary endpoint Status CT Identifier In collaboration with Chugai Phase I/II COMPOSER N=59 ☐ Healthy volunteers and treatment naïve and pretreated patients with PNH: Part 1: Single ascending dose study in healthy subjects Part 2: Intra-patient single ascending dose study in PNH patients Part 3: Multiple-dose study in PNH patients ■ Part 4: Dose confirmation in PNH patients • Safety, PK, PD Part 1: FPI Q4 2016 Part 2/3: FPI Q2 2017 Part 4: FPI Q2 2019 • Nonclinical data published in Scientific Reports 2017 Apr; 7(1):1080 Data presented for Part 2 and 3 at ASH 2018 and 2019 NCT03157635 " ARM A: Crovalimab Phase III COMMODORE 1 N=250 " " ARM B: Eculizumab ▪ ARM C: Patients switching to crovalimab from ravulizumab, higher than labeled doses of eculizumab & C5 SNP patients (descriptive-arm) Non-inferiority of crovalimab compared to eculizumab - mean % change in LDH level (measure of haemolysis) from baseline to week 25 FPI Q3 2020 ASH-American Society of Hematology; PNH=Paroxysmal nocturnal hemoglobinuria; PK/PD=Pharmacokinetics/Pharmacodynamics; LDH-Lactate Dehydrogenase NCT04432584 139 Immunology#140Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor naive patients Paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor naive patients (China only) Phase/study # of patients Design Phase III COMMODORE 2 N=200 ARM A: Crovalimab ARM B: Eculizumab Phase III COMMODORE 3 N=51 ▪ Crovalimab loading dose IV on Day 1, followed by weekly crovalimab SC doses for 4 weeks Non-inferiority of crovalimab compared to eculizumab: - % patients with transfusion avoidance from baseline through week 25 Primary endpoint Status CT Identifier - % patients with haemolysis control, as measured by LDH <=1.5ULN from week 5-25 FPI Q4 2020 NCT04434092 ▪ Percentage of patients with transfusion avoidance from baseline through week 25 Mean percentage of participants with hemolysis control (week 5 through week 25) ▪ FPI Q1 2021 ■ Recruitment completed Q3 2021 ▪ Study met its co-primary endpoints Q1 2022 NCT04654468 In collaboration with Chugai LDH-Lactate Dehydrogenase; ULN=Upper Limit of Normal; IV=Intravenous; SC-Subcutaneous 140 Roche Immunology#141Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Atypical hemolytic uremic syndrome (aHUS) study 1-adults Atypical hemolytic uremic syndrome (aHUS) study 2 - paediatrics Phase/study # of patients Design Phase III COMMUTE-a Single-arm study of aHUS patients N=90 ■ Cohort 1: not previously treated with C5i Cohort 2: switching from C5i ■ Cohort 3: known C5 polymorphism Primary endpoint ■ Cohort 1+3: proportion of patients with complete TMA response anytime between baseline and week 25 Cohort 2: proportion of patients with maintained TMA control from baseline through week 25 Status CT Identifier FPI Q4 2021 NCT04861259 In collaboration with Chugai aHUS=Atypical Hemolytic Uremic Syndrome; C5i-C5 inhibitor; TMA-thrombotic microangiopathy " Phase III COMMUTE-P N=35 Single-arm study of aHUS patients Cohort 1: not previously treated with C5i Cohort 2: switching from C5i≤18y/o Cohort 1: proportion of patients with complete TMA response anytime between baseline and week 25 Cohort 2: proportion of patients with maintained TMA control from baseline through week 25 FPI Q4 2021 NCT04958265 141 Roche Immunology#142Crovalimab (RG6107; SKY59) A humanized monoclonal antibody against complement C5 Indication Sickle cell disease (SCD) acute treatment Sickle cell disease (SCD) chronic VOC prevention Phase/study # of patients Design Phase lb CROSSWALK-a N=30 ARM A: Crovalimab ARM B: Placebo Primary endpoint Safety FPI Q1 2022 Status CT Identifier SCD-Sickle Cell Disease; VOC-Vaso-occlusive crises NCT04912869 Phase lla CROSSWALK-C N=90 ARM A: Crovalimab ARM B: Placebo VOC rate, up to 48 weeks ☐ FPI Q1 2022 NCT05075824 142 Roche Immunology#143Crenezumab (RG7412) Humanized monoclonal antibody targeting all forms of Ab Indication Phase/study Alzheimer's prevention initiative (API) Colombia Phase II Cognition study # of patients N=252 ARM A: PSEN1 E280A mutation carriers receive crenezumab SC or IV ARM B: PSEN1 E280A mutation carriers receive placebo Design ▪ ARM C: non-mutation carriers receive placebo Primary endpoint Status ▪ Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score at 260 weeks treatment Annualized rate of change in an Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT) FPI Q4 2013 ▪ Recruitment completed Q1 2017 Study did not meet its co-primary endpoints Q2 2022 CT Identifier In collaboration with AC Immune Ab-amyloid-beta; SC-Subcutaneous; IV=Intravenous NCT01998841 143 Roche Neuroscience#144Gantenerumab (RG1450) Fully human monoclonal antibody binding aggregated forms of AB Indication Prodromal to mild Alzheimer's disease Phase/study # of patients Phase III GRADUATE 1 N=1,016 104-week SC treatment period: ARM A: Gantenerumab Design ☐ ARM B: Placebo Phase III GRADUATE 2 N=1,016 104-week SC treatment period: ARM A: Gantenerumab ARM B: Placebo ■ Change in CDR-SOB at 27 months Primary endpoint Status CT Identifier ▪ Change in CDR-SOB at 27 months FPI Q3 2018 Phase II GRADUATION N=192 104-week SC treatment period: gantenerumab SC treatment q1w dosing regimen Change from baseline in deposited amyloid (PET centiloid levels) ▪ Recruitment completed Q3 2021 FPI Q2 2018 ☐ ■ FPI Q4 2020 Recruitment completed Q2 2020 ▪ Recruitment completed Q2 2020 BTD granted by FDA Sep 2021 NCT03443973 NCT03444870 In collaboration with MorphoSys AG AB-amyloid-beta; CDR-SOB-Clinical Dementia Rating Scale Sum of Boxes; SC-Subcutaneous; BTD=Breakthrough Therapy Designation; PET= positron emission tomography NCT04592341 Roche 144 Neuroscience#145Gantenerumab (RG1450) Fully human monoclonal antibody binding aggregated forms of AB Indication Prodromal Alzheimer's disease Mild Alzheimer's disease Roche Cognitively unimpaired participants at risk for or at the earliest stages of Alzheimer's disease Phase/study # of patients Design Primary endpoint Status Phase II/III Scarlet ROAD¹ N=799 104-week SC treatment period: ▪ ARM A: Gantenerumab (225 mg) ARM B: Gantenerumab (105 mg) ARM C: Placebo Change in CDR-SOB at 2 years Sub-study: change in brain amyloid by PET at 2 years ■ Phase I PET data: Archives of Neurology, 2012 Feb;69(2):198-207 ▪ Recruitment completed Q4 2013 ■ Dosing stopped due to futility Q4 2014 ■ FPI in open label extension study Q4 2015 Published in Alzheimers Res Ther 2017 Dec 8;9(1):95 Phase III Marguerite ROAD¹ N=389 104-week SC treatment period: ARM B: Placebo ◉ ▪ ARM A: Gantenerumab Change in ADAS-Cog and CDR-SOB at 2 years (co- primary) ■ FPI Q1 2014 Phase III SKYLINE² N=1200 ARM A: Gantenerumab q1w or q2w (patient preference) ARM B: Placebo Cognitive composite (PACC5) FPI Q2 2022 Recruitment stopped Q4 2015 ■ FPI Q1 2016 for open label extension CT Identifier NCT01224106 36 OLE data published in J Prev Alzheimers Dis 2021;8(1):3-6 NCT02051608 NCT05256134 'In collaboration with MorphoSys AG; 2In collaboration with Banner Alzheimer's Institute AB-amyloid-beta; CDR-SOB-Clinical Dementia Rating Scale Sum of Boxes; PET= positron emission tomography; ADAS-cog-Alzheimer's Disease Assessment Scale cognitive subscale; SC=Subcutaneous; OLE=Open Label Extension; PACC5=Preclinical Alzheimer's Cognitive Composite 145 Neuroscience#146Tominersen (RG6042, HTT ASO) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington's disease Phase/study # of patients Design Phase I/lla Phase II OLE N=46 N=46 " ▪ Multiple ascending doses of tominersen administered intrathecally to adult patients with early manifest Huntington's Disease " ▪ Patients from phase I are enrolled into OLE Primary endpoint ▪ Safety, tolerability and PK/PD ■ FPI Q3 2015 Status CT Identifier Data presented at CHDI 2018 and AAN 2018 PRIME designation granted 2018 Published in NEJM 2019; 380:2307-2316 NCT02519036 ■ Longer term safety, tolerability and PK/PD ▪ FPI Q1 2018 ▪ PK/PD data presented at AAN 2019 Update presented at CHDI 2020 • Study completed, patients moved to GEN-EXTEND OLE NCT03342053 In collaboration with lonis Pharmaceuticals HTT=Huntingtin; PK/PD=Pharmacokinetics/Pharmacodynamics; PRIME=Priority medicines; OLE=Open Label Extension; AAN-American Academy of Neurology; NEJM-New England Journal of Medicine; CHDI-Huntington's Disease Association of Ireland 146 Roche Neuroscience#147Tominersen (RG6042, HTT ASO) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington's disease Phase/study Phase III Generation HD1 N=791 # of patients ARM A: Tominersen 120mg q2w ARM B: Tominersen 120mg q4m ARM C: Placebo q2w Design ▪ CUHDRS globally Primary endpoint TFC USA only Status CT Identifier Phase III GEN-EXTEND N=1,050 Roche OLE study in patients participating in prior Roche and Genentech sponsored studies ARM A: Tominersen 120mg q2w • ARM B: Tominersen 120mg q4m ■ Long term safety, tolerability FPI Jan 2019 ▪ Q1 2019 protocol modified to allow for bi-monthly vs four-monthly dosing, FPI for new protocol July 2019 ■ Recruitment completed Q2 2020 ■ Dosing stopped in Q1 2021 based on IDMC recommendation regarding the potential benefit/risk profile for study participants. No new safety signals identified. Data presented at EHDN and CHDI 2022 • ⚫ FPI Q2 2019 Dosing stopped in Q1 2021 NCT03761849 NCT03842969 In collaboration with lonis Pharmaceuticals CUHDRS=composite Unified Huntington's Disease Rating Scale; TFC=total function capacity; HTT=Huntingtin; OLE=Open Label Extension; IDMC-Independent Data Monitoring Committee; CHDI-Huntington's Disease Association of Ireland; EHDN-European Huntington's Disease Network 147 Neuroscience#148Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) Phase/study Phase III FENtrepid Phase III FENhance 1 N=736 # of patients N=946 ARM A: Fenebrutinib twice daily oral ARM B: Ocrevus 2x300mg IV q24w ARM A: Fenebrutinib twice daily oral ARM B: Teriflunomide once daily oral Design Time to onset of CCDP12 Primary endpoint ■ FPI Q4 2020 Status CT Identifier NCT04544449 IV-Intravenous; CCDP12-Composite 12-week confirmed disability progression Time to onset of CCDP12 and annualized relapse rate ☐ FPI Q1 2021 NCT04586023 Phase III FENhance 2 N=736 ARM A: Fenebrutinib twice daily oral ARM B: Teriflunomide once daily oral Time to onset of CCDP12 and annualized relapse rate ▪ FPI Q1 2021 NCT04586010 148 Roche Neuroscience#149Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (PRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#150PRED oncology development programs -1 Molecule Indication Solid tumors Phase # of patients Status Oncology ~150 FPI Q2 2018 Data presented at ESMO 2020 Recruitment completed Q2 2021 Roche CT Identifier FAP-4-1BBL (RG7827) 3L+ MSS MCRC FPI Q3 2021 lb 80 NCT04826003 Combination study with cibisatamab Part I: FPI Q3 2019 CD19-4-1BBL (RG6076) R/R B cell non-Hodgkin's lymphoma 362 NCT04077723 Part II: FPI Q3 2020 Part I: FPI Q2 2020; recruitment completed Q4 PD1-IL2v (RG6279) Solid tumors 348 2021 NCT04303858 Part II: FPI Q1 2022 FPI Q4 2014 la 149 NCT02324257 Data presented at ASCO 2017 cibisatamab (CEA x CD3, RG7802) CEA-positive solid tumors FPI Q1 2016 lb 228 NCT02650713 Data presented at ASCO 2017 3L+ MSS MCRC Solid tumors PD1-LAG3 (RG6139) Solid tumors lb 46 FPI Q1 2019 NCT03866239 | 320 FPI Q4 2019 NCT04140500 || = 210 FPI Q2 2021 Randomized trial, compared with nivolumab NCT04785820 TALIOS 150#151PRED oncology development programs -2 Roche Molecule Indication Phase # of patients Status CT Identifier Oncology Solid tumors | 110 FPI Q4 2019 NCT04158583 CD25 (RG6292) Advanced and metastatic solid Part I: FPI Q1 2021 160 NCT04642365 tumors Part II: FPI Q4 2021 Anti-GPRC5D (RG6234) Multiple myeloma 240 FPI Q4 2020 NCT04557150 HLA-A2-WT1 x CD3 (RG6007) AML | 160 FPI Q4 2020 FAP-CD40 (RG6189) Solid tumors 280 FPI Q2 2021 HLA-A2-MAGE-A4 x CD3 (RG6129) Solid tumors 180 FPI Q1 2022 NCT04580121 NCT04857138 NCT05129280 BRAFI (3) (RG6344) Solid tumors 292 FPI Q1 2022 FPI Q1 2022 CD19xCD28 (RG6333) R/R B cell non-Hodgkin's lymphoma | ~200 ISRCTN13713 551 NCT05219513 Combination study with glofitamab EGFRvlllxCD3 (RG6156) Glioblastoma ~200 FPI Q2 2022 NCT05187624 151#152PRED neuroscience development programs -1 Molecule Indication Phase # of patients Status Neuroscience Brain Shuttle-gantenerumab (BS- gantenerumab, RG6102) Alzheimer's disease lla Brain Shuttle-CD20 (BS-CD20, RG6035) Multiple sclerosis || = ralmitaront (partial TAAR1 agonist, RG7906) Schizophrenia || prasinezumab¹ || = (anti-aSynuclein, RG7935, PRX002) Parkinson's disease llb 19 Roche CT Identifier ~120 FPI Q1 2021 30 36 247 316 FPI Q3 2021 FPI Q4 2018; Recruitment completed Q3 2019 FPI Q4 2019 The study did not meet its primary endpoint, but showed a reduced clinical decline of core motor signs (MDS UPDRS partIII). Data presented at MDS & ADPD 2020-22. The Open Label Extension is ongoing. NCT04639050 ISRCTN16295 177 NCT03669640 (TWAIN I) NCT03100149 (PASADENA) 575 FPI Q2 2021 alogabat (GABA-Aa5 PAM, RG7816) NME (RG7637) rugonersen Autism spectrum disorder || 105 FPI Q1 2021 Neurodevelopmental disorders 80 FPI Q3 2020 Angelman syndrome 66 FPI Q3 2020 (UBE3A LNA, RG6091) NME (RG6182) Neurodegenerative disorder 50 30 FPI Q4 2020 Partner: 1Prothena BS Brain Shuttle NCT04777331 (PADOVA) NCT04299464 (Aurora) NCT04475848 NCT04428281 152#153PRED neuroscience development programs -2 Molecule Indication Phase # of patients Status Neuroscience NME (RG6289) Alzheimer's disease | 138 FPI Q4 2021 NME (RG6163) Psychiatric disorders | 84 FPI Q1 2022 Partner: ¹Prothena; BS-Brain Shuttle Roche CT Identifier 153#154PRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status Immunology FPI Q4 2021 Ulcerative colitis lb 18 selnoflast (NLRP3i, RG6418) Recruitment completed Q2 2022 Chronic obstructive pulmonary disease lb 102 FPI Q2 2022 NME (RG6179)¹ VEGF-Ang2 DutaFab (RG6120) NME (RG7774) Partner: 1Sesen Bio DME Ophthalmology | 90 FPI Q3 2019 || 160 FPI Q4 2021 || 320 FPI Q4 2021 | ~50 FPI Q4 2020 = 135 FPI Q2 2020 nAMD Retinal disease || Roche CT Identifier DOVETAIL NCT05151744 (BARDENAS) NCT05151731 (ALLUVIUM) NCT04567303 NCT04265261 (CANBERRA) 154#155PRED infectious diseases development programs Roche Molecule Indication Phase # of patients Status CT Identifier Infectious Diseases FPI Q4 2016 TLR7 agonist (3) (RG7854) Chronic hepatitis B | 150 NCT02956850 Data presented at APASL 2019 FPI Q4 2016 1/11 192 NCT02952924 Data presented at EASL 2018, 2019 & 2020 CPAM (RG7907) Chronic hepatitis B FPI Q1 2021 22 NCT04729309 Recruitment completed Q2 2021 TLR7 agonist (3)/ CPAM/siRNA/ PDL1 LNA Chronic hepatitis B || 275 FPI Q3 2020 (RG7854/RG7907/RG6346/RG6084) PDL1 LNA (RG6084) Chronic hepatitis B Abx MCP (RG6006) A. baumannii infections Abx MCP-antibiotic macrocyclic peptide FPI Q1 2019 35 Part la: completed Part lb: initiated 204 FPI Q4 2020 NCT04225715 (PIRANGA) NCT04605718 155#156Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (PRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#157gRED oncology development programs Roche Molecule Indication Phase # of patients Status CT Identifier Oncology KRAS G12C (RG6330) cevostamab (anti-FcRH5 x CD3; RG6160) runimotamab (HER2 x CD3, RG6194) NME (RG6286) Metastatic solid tumors with KRAS G12C mutation 270 FPI Q3 2020 NCT04449874 FPI Q3 2017 R/R multiple myeloma 300 NCT03275103 Data presented at ASH 2020, ASH 2021 Metastatic HER2-expressing cancers 440 FPI Q2 2018 NCT03448042 Locally advanced or metastatic 67 FPI Q3 2020 NCT04468607 colorectal cancer Solid tumors 1/11 250 FPI Q1 2020 IL15/IL15Ra-Fc (RG6323)1 R/R multiple myeloma | 60 FPI Q2 2022 NCT04250155 NCT05243342 FPI Q4 2017 Solid tumors la/llb 271 autogene cevumeran (Individualized Neoantigen-Specific Therapy (iNeST); RG6180)² 1L advanced melanoma || = 132 FPI Q1 2019 Data presented at AACR 2020 Recruitment completed Q1 2022 NCT03289962 NCT03815058 (IMcode001) NCT04252339 SHP2i (RG6344) Solid tumors la ~50 FPI Q1 2020 belvarafenib (RG6185)³ nRASmt CPI-experienced melanoma lb 83 FPI Q2 2021 NCT04835805 ISRCTN92655 NME (RG6392) Oncology 60 FPI Q4 2021 801 Partner: 1Xencor, 2BioNTech, ³Hanmi 157#158gRED immunology and ophthalmology development programs Molecule efmarodocokin alfa (IL-22Fc, RG7880) Indication aGVHD Phase # of patients Status Immunology lb 18 FPI Q4 2020 Roche CT Identifier NCT04539470 FPI Q1 2020 Inflammatory bowel disease | 68 NME (RG6287, GDC-8264) Recruitment completed Q3 2021 EUDRACT201 9-002613-19 Inflammatory diseases 16 FPI Q4 2021 NME (RG6315, MTBT1466A) Immunologic disorders ~24 FPI Q3 2020 astegolimab (Anti-ST2, Chronic obstructive pulmonary llb 930 FPI Q4 2021 NCT05037929 (RG6149, AMG 282, MSTT1041A)1 disease NME (RG6341, GDC-6599) Asthma la/lb 84 FPI Q4 2021 Ophthalmology galegenimab Geographic atrophy || 360 FPI Q2 2019 (HtrA1, RG6147) NME (RG6312) NME (RG6351) Geographic atrophy la 63 FPI Q4 2020 Retinal disease | 42-78 FPI Q2 2022 Partner: 1Amgen NCT03972709 (GALLEGO) NCT04615325 158#159gRED neuroscience and infectious diseases development programs Molecule Indication Prodromal to mild Alzheimer's disease semorinemab (RG6100)1 Mild-to-moderate Alzheimer's disease Phase # of patients Status Neuroscience FPI Q4 2017 || 457 Primary endpoint not met Q3 2020 || Roche CT Identifier NCT03289143 (TAURIEL) Data presented at CTAD 2020 One of two co-primary endpoints met Q3 2021 Data presented at CTAD 2021 FPI Q1 2019 272 The Open Label Extension is ongoing NCT03828747 (LAURIET) Infectious Diseases LepB inhibitor (RG6319) Complicated urinary tract infection 56 FPI Q1 2022 Partner: 1AC Immune 159#160Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#161Hemophilia A Unique gene therapy platform Molecule Indication Phase/study # of patients Design Phase I N=100 SPK-8011 (RG6357) Hemophilia A Phase I/II N=30 ◉ Gene transfer, dose-finding safety, tolerability, and efficacy study of SPK-8011 ■Long term follow up study of patients who have received SPK-8011 in any prior Spark- sponsored SPK-8011 study Safety Primary endpoint Ongoing Status CT Identifier NCT03432520 • Safety and changes from baseline in FVIII activity levels at week 52 " Spark THERAPEUTICS TM SPK-8016 (RG6358) Hemophilia A with inhibitors to Factor VIII Roche " Phase I/II N=30 Gene transfer, dose-finding safety, tolerability, and efficacy study of SPK-8016 in individuals with FVIII inhibitors Safety; peak and steady state FVIII activity levels at week 52 ☐ FPI Q1 2017 ■ Updated data presented at ISTH 2020 and 2021 Recruitment completed Q1 2021 ◉ FPI Q1 2019 Data published in NEJM 2021; 385:1961-1973 ISTH=International Society on Thrombosis and Haemostasis; NEJM-New England Journal of Medicine NCT03003533 NCT03734588 161 Hemophilia#162Pompe disease Unique gene therapy platform Molecule SPK-3006 (RG6359) Indication Phase/study # of patients ▪ Gene transfer study for late-onset Pompe disease Pompe disease Phase I/II RESOLUTE N=20 Design Primary endpoint Status CT Identifier Safety FPI Q4 2020 NCT04093349 Spark THERAPEUTICS TM 162 Roche Metabolic Diseases#163Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#164Geographical sales split by Divisions and Group* CHFM HY 2021 HY 2022 % change CER Pharmaceuticals Division 21,671 22,347 +3 United States 10,802 11,363 +1 Europe 4,485 4,104 -4 Japan 1,808 2,202 +34 International 4,576 4,678 +2 Diagnostics Division 9,042 9,948 +11 United States 1,849 2,511 +31 Europe 3,574 2,799 -17 Japan 324 380 +29 International 3,295 4,258 +30 Group 30,713 32,295 +5 United States 12,651 13,874 +5 Europe 8,059 6,903 -10 Japan 2,132 2,582 +33 International 7,871 8,936 +14 CER-Constant Exchange Rates; * Geographical sales split shown here does not represent operational organization Roche 164#165Pharma Division sales HY 2022 Top 20 products Roche Global US Europe Japan International CHFM % CER CHFM % CER CHFM % CER CHFM % CER CHFM % CER Ocrevus 2,910 17 2,140 11 539 34 231 43 Perjeta 2,061 5 740 1 457 -17 120 -1 744 34 Hemlibra 1,826 30 1,098 26 360 30 180 19 188 89 Tecentriq 1,758 11 951 13 383 19 218 -7 206 9 Actemra/RoActemra 1,455 -10 664 -7 420 -3 174 4 197 -37 Herceptin 1,179 -16 263 -27 233 -11 28 -28 655 -11 Avastin 1,142 -29 342 -38 116 -53 263 -13 421 -20 MabThera 1,117 -21 691 -22 Kadcyla 1,074 14 415 -1 Xolair 1,025 11 1,025 11 Alecensa 745 19 207 19 Ronapreve 609 11 ༄ཤྩ'¥8 105 -17 17 -8 304 -19 350 10 68 23 23 241 52 - 149 7 114 6 275 65 -86 467 7275 37 -30 Lucentis 572 -17 572 -17 TNKase/Activase 559 -10 531 -10 Evrysdi 500 106 227 32 152 489 38 Esbriet 457 -14 313 -17 127 -2 Gazyva 349 8 161 2 95 -6 28 20 -2 G187 28 1 83 65 -36 65 88 Phesgo 325 241 138 155 163 338 24 403 Pulmozyme 279 0 184 2 51 -11 44 4 CellCept 270 -8 20 -16 68 -7 29 -8 153 -6 Pharma Division 22,347 3 11,363 1 4,104 -4 2,202 34 4,678 2 CER = Constant Exchange Rates (avg. full year 2021) 165#166Pharma Division sales HY 2022 Product sales Pharmaceuticals Division Roche Global US Europe Japan International CHFM % CER CHFM % CER CHFM % CER CHFM % CER CHFM % CER Ocrevus Perjeta 2,910 17 2,140 11 539 34 231 43 2,061 5 740 Hemlibra 1,826 30 1,098 Tecentriq 1,758 11 951 Actemra/RoActemra 1,455 -10 Herceptin 1,179 -16 Avastin 1,142 -29 MabThera 1,117 -21 Kadcyla 1,074 14 Xolair 1,025 11 1,025 Alecensa 745 19 Ronapreve 609 11 Lucentis 572 -17 TNKase/Activase 559 -10 Evrysdi 500 106 Esbriet 457 -14 Gazyva 349 8 Phesgo 325 241 Pulmozyme 279 0 CellCept 270 -8 Polivy 177 91 Erivedge 131 2 Vabysmo 109 Enspryng 84 132 Rozlytrek 34 54 Cotellic 24 4 1 * * * 5 * 2 6022^ 664 263 342 -38 691 -22 415 -17 -10 32 -17 2 155 2 -16 86 -3 192 ២ន នី, ៤៩៩សគឺសង់នម់ង់, ≥ ន់៩ ១៨៩ → 8៩ , ៥៩៩ដ៦៖ 80 457 -17 360 30 383 19 420 -3 233 -11 116 -53 105 -17 350 10 - 149 7 -86 ទី៩, ៩-៩៩ន៨៩៩ 120 744 180 19 188 218 -7 206 174 197 -37 -28 655 -11 263 -13 421 -20 -8 304 -19 23 241 114 467 a 275 77 28 127 ៩៩៩ឬទី៖ជនី 152 489 38 83 -2 17 95 -6 28 2 163 338 65 24 403 51 -11 44 -7 29 16 6 4 Gavreto 12 9 58 M 5 199 1 FG 23 ∞ * 153 43 11 19 22222 53-58122 34 89 9 52 88 4 -6 1 55 3 ཎྜ༩ 102 1 201 18 4 262 9 16 3 Xofluza 4 -145 1 -117 3 Susvimo 2 2 Other Products 1,558 -13 356 -19 175 -21 350 50 -2 12 677 -14 Pharma Division 22,347 3 11,363 4,104 -4 2,202 34 4,678 2 CER Constant Exchange Rates (avg. full year 2021); * over 500% 166#167Pharma Division CER sales growth¹ in % Global top 20 products Roche Q1/21 Q2/21 Q3/21 Q4/21 Q1/22 Q2/22 Ocrevus 16 31 7 25 18 17 Perjeta 2 7 2 3 1 9 Hemlibra 33 58 37 38 30 31 Tecentriq 26 31 23 17 8 13 Actemra/RoActemra 22 12 57 21 3 -23 Herceptin -35 -35 -26 -6 -19 -11 Avastin -40 -40 -37 -30 -32 -27 MabThera -46 -34 -42 -26 -21 -20 Kadcyla 17 21 11 16 9 18 Xolair -6 3 8 14 9 13 Alecensa 14 25 18 15 23 16 Ronapreve 272 -91 Lucentis -7 TNKase/Activase -17 23 2 -10 2 -26 -9 3 3 -20 1 Evrysdi Esbriet -8 Gazyva -2 18 10 ܂ Phesgo Pulmozyme CellCept -23 -5 जेजे -13 -3 * 50 * 7 M 347 མ་རྩ་ 189 65 -5 -7 -6 -21 10 10 7 9 -7 3 -2 * 52 410 168 -3 2 -12 -3 CER = Constant Exchange Rates; * over 500%; 1Q1-Q4/21 vs Q1-Q4/20; Q1-Q2/22 vs Q1-Q2/21 167#168Pharma Division CER sales growth¹ in % Top 20 products by region Roche US Europe Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Japan Q4 International Q1 Q2 Q3 Q4 Q1 Q2 Ocrevus 0 23 12 10 36 26 34 34 35 51 29 62 Perjeta 2 -2 -1 4 -8 -8 -21 -12 0 -3 -1 Hemlibra 36 33 28 24 26 53 31 29 Tecentriq 10 2 10 15 16 41 14 24 Actemra/RoActemra 143 67 22 -31 10 18 -4 -2 Herceptin -52 -34 -26 -29 -20 -3 -13 -9 2225 29 30 15 24 75 34 -5 -9 -37 -36 -30 -27 Avastin -50 -45 -39 -36 MabThera -49 -32 -20 -24 Kadcyla 0 3 Xolair 8 14 Alecensa 9 18 32001 -69 -49 -56 -49 5 LO -33 -13 -19 -16 -1 16 16 8 12 550 TE523222 -1 16 24 32 37 138 55 63 115 62 24 0 17 5 12 -2 -14 -55 -30 -44 -7 17 -18 -3 222 -30 0 -12 -13 -17 -15 59 42 28 -11 -24 -23 -17 13 25 14 7 9 5 80 11 LO FLO LO Ronapreve - -61 -99 -2 -25 -15 -23 -13 20 16 38 26 81 7 5 40 25 45 29 -68 ៩៤ 3778 25 280 Lucentis -10 2 -26 -9 1 TNKase/Activase 2 * 22 -21 1 17 7 -3 4 Evrysdi 112 36 28 227 * * -5 Esbriet -2 -7 -4 -28 0 0 -5 1 -73 -36 -36 -36 Gazyva 3 * 11 0 3 10 2 -5 -8 10 -7 8 -10 43 56 75 101 Phesgo 236 187 134 * * * 188 278 Pulmozyme -10 6 0 5 -10 -15 -11 -12 -18 CellCept -18 -31 -15 -17 -2 3 -7 -7 292 22 11 44 -7 -9 -8 -9 18 = 12 22 45 13 w& -4 14 3 -14 3 CER = Constant Exchange Rates; * over 500%; 1Q3-Q4/21 vs Q3-Q4/20; Q1-Q2/22 vs Q1-Q2/21 168#169CER sales growth (%) Quarterly development 2021 vs. 2020 2022 vs. 2021 Q1 Q2 Q3 Q4 Q1 Q2 Pharmaceuticals Division -9 4 5 LO 14 19 6 0 United States -14 0 0 8 2 1 Europe -6 15 1 19 -1 -6 Japan -7 7 60 46 69 International 0 4 2 9 0 Diagnostics Division 55 48 18 8 24 Roche Group 3 14 8 12 11 MOO 3 4 0 0 CER-Constant Exchange Rates Roche 169#170Ocrevus Global sales CHFbn CER growth +17% Regional sales 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 2,910m • US: Moving into earlier lines displacing orals; COVID-19 impact still felt • EU: Moving into earlier lines displacing orals; COVID-19 impact still felt CER-Constant Exchange Rates US CER growth +11% Europe +34% International +43% Roche 170#171Perjeta Global sales CHFbn CER growth +5% Regional sales CER growth US +1% 2.5 Europe -17% 2.0 1.5 Japan -1% 1.0 0.5 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 2,061m • US: Cannibalization from Phesgo • ● EU: Cannibalization from Phesgo International: Accelerated growth in all regions CER=Constant Exchange Rates International +34% Roche 171#172Hemlibra Global sales CHFbn CER growth +30% Regional sales CER growth US +26% 2.0 Europe +30% 1.6 1.2 0.8 0.4 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,826m • US: Continued share gains in non-inhibitor patients • Japan +19% International +89% EU: Continued share gains in non-inhibitor severe patients with market shares > 50% in France, UK and GER, Italy, Spain >20% • Japan: Strong uptake in non-inhibitor patients International: Accelerating momentum driven by becoming new SoC in key markets CER-Constant Exchange Rates Roche 172#173Tecentriq Global sales CHFbn CER growth +11% Regional sales CER growth US +13% 2.0 1.6 1.2 0.8 0.4 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,758m • US: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC • EU: Growth driven by first-in-class launches in adjuvant PDL1+ NSCLC, in 1L HCC and 1L SCLC ● Japan: 11% price cut in Q3 2021 CER-Constant Exchange Rates Europe +19% Japan -7% International +9% Roche 173#174Actemra/RoActemra Global sales CHFbn CER growth -10% Regional sales CER growth US -7% 1.8 1.5 1.2 0.9 0.6 0.3 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,455m Europe -3% Japan +4% International -37% • US: Actemra SC share in RA keeps increasing; Limited COVID-19 sales in Q2 as hospitalizations have come down significantly • . Roche EU: Market leadership in 1L RA monotherapy maintained; Limited COVID-19 sales in Q2 as hospitalizations have come down significantly International: Limited COVID-19 sales in Q2 as hospitalizations have come down significantly CER=Constant Exchange Rates 174#175Herceptin Global sales CHFbn CER growth -16% Regional sales CER growth US -27% 3.6 Europe -11% 3.0 Japan -28% 2.4 1.8 1.2 International -11% 0.6 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,179m • US: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo • EU: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo • Japan: Decline due to biosimilars International: Decline due to biosimilars CER-Constant Exchange Rates Roche 175#176Avastin Global sales CHFbn CER growth -29% Regional sales CER growth US -38% 4.2 Europe -53% 3.5 2.8 Japan -13% 2.1 1.4 International -20% 0.7 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,142m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing • Japan: Limited decline due to biosimilars with narrow labels International: Biosimilar erosion slowing CER-Constant Exchange Rates Roche 176#177Rituxan / Mabthera CER growth -22% Europe -17% Japan -8% Global sales CHFbn CER growth -21% Regional sales 3.6 US 3.0 2.4 1.8 1.2 0.6 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,117m • US: Biosimilar erosion slowing • EU: Biosimilar erosion slowing . Japan: Biosimilar erosion slowing International: Biosimilar erosion slowing CER-Constant Exchange Rates International -19% Roche 177#178Kadcyla CER growth -1% Europe +10% Global sales CHFbn CER growth +14% Regional sales 1.2 US 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,074m • US: Growth in adjuvant eBC; share decline in metastatic BC due to competition • . EU: Strong uptake in adjuvant eBC in patients with residual disease after neoadjuvant treatment International: Growth driven by all regions CER=Constant Exchange Rates Japan +23% International +52% Roche 178#179Xolair Global sales CHFbn CER growth +11% Regional sales CER growth 1.2 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 US +11% HY 2022 sales of CHF 1,025m • US: Xolair remains market leader in growing biologics asthma market; Growth driven by chronic idiopathic urticaria (CIU) CER-Constant Exchange Rates Roche 179#180Alecensa Global sales CHFbn CER growth +19% Regional sales CER growth US +19% 0.8 0.7 0.6 Europe +7% 0.5 0.4 Japan +6% 0.3 0.2 0.1 International +37% 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 745m • US: New patient share in 1L at around 70% • • EU: EU-5 new patient share in 1L at around 70% Japan: New patient share in 1L reaching >70% International: Strong growth driven by China CER-Constant Exchange Rates Roche 180#181Ronapreve Global sales CER growth Regional sales CER growth CHFbn +11% 0.7 International -30% 0.6 0.5 Europe -86% 0.4 0.3 Japan n/a 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 609m · EU: Limited sales potential left as Ronapreve has low activity against Omicron variants . Japan: Additional sales to the government (overall CHF 1.6bn for FY 2022) CER-Constant Exchange Rates Roche 181#182Lucentis Global sales CHFbn CER growth -17% Regional sales CER growth 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 572m • Impacted by switching to Vabysmo and upcoming biosimilar launches CER-Constant Exchange Rates US -17% Roche 182#183TNKase / Activase Global sales CHFbn CER growth -10% Regional sales CER growth US -10% 0.8 0.7 0.6 0.5 0.4 0.3 0.2 International +1% 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 559m • US: Sales impacted by COVID-19 and purchasing patterns CER-Constant Exchange Rates Roche 183#184Evrysdi Global sales CHFbn CER growth Regional sales +106% CER growth US 0.6 +32% 0.5 0.4 0.3 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 500m • US: Strong growth driven by switch and treatment-naïve patients; market share increasing >20% • EU: Excellent growth driven by Germany and launches in key markets UK, Italy and France . International: Strong growth in all regions CER=Constant Exchange Rates Europe +489% Japan n/a International +65% Roche 184#185Esbriet Global sales CHFbn CER growth -14% Regional sales CER growth US -17% 0.6 0.5 Europe -2% 0.4 0.3 0.2 0.1 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 457m • US: Generics have entered the market in Q2 • EU: Generic entry expected soon CER-Constant Exchange Rates International -36% Roche 185#186Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#187HY 2022: Diagnostics Division CER growth By Region and Customer Area (vs. 2021) Roche Reported Restatement³ Global EMEA¹ NOA CHFm %CER CHFm %CER CHFm %CER APAC CHFm %CER LATAM CHFm %CER Global NOA CHFm %CER CHFm %CER CHFm %CER EMEA¹ APAC LATAM CHFm %CER CHFm %CER Core Lab 2,3 Point of Care³ Molecular Lab³ Diabetes Care Pathology Lab Diagnostics Div. 3,834 4 2,289 2,341 1,313 6 714 2 1,521 3 286 12 3,875 4 1,352 5 43 585 -53 802 600 830 714 72 -30 2,609 46 652 -50 716 974 333 1 1,521 908 713 3 286 12 75 -28 7 838 2 888 7 544 20 71 -19 1,980 1 732 2 714 -1 466 6 68 -21 832 -5 454 -3 116 -30 144 1 118 24 832 -5 652 10 160 11 348 8 132 13 12 30 652 10 160 454 -3 116 -30 11 144 1 118 24 348 8 132 13 12 30 50 9,948 11 3,350 -14 2,868 34 3,171 39 559 2 9,948 11 3,350-14 || 2,868 34 3,171 39 559 2 CER=Constant Exchange Rates; ' Europe, Middle East and Africa; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21=194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF. 187#188Diagnostics Division quarterly sales and CER growth¹ Reported Restatement³ Roche Q121 Q2 21 Q3 21 Q2 22 CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER Q4 21 Q122 Q121 Q2 21 Q3 21 Q122 Q2 22 CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER Q4 21 Core Lab 2,3 Point of Care³ Molecular Lab³ Diabetes Care Pathology Lab Diagnostics Div. 4,330 1,765 31 716 281 1,107 86 1,961 36 900 424 1,884 12 442 143 525 1,863 10 -2 1,873 8 1,961 1 1,786 31 1,984 36 1,907 12 1,883 9 1,896 8 1,979 1 1,302 84 987 10 806 255 992 464 617 222 719 1,109 19 1,238 21 1,358 15 1,376 26 965 -13 996 87 994 9 1,040 5 15 1,144 7 1,466 84 1,143 15 1,189 21 791 -20 460 13 434 7 400 -7 396 -2 417 -7 415 -3 460 13 434 7 400 -7 396 -2 417 -7 415 -3 282 9 308 32 32 299 4 313 7 318 14 334 7 282 9 308 32 299 + 313 7 318 14 334 7 55 4,712 48 4,263 18 4,455 8 5,286 24 24 4,662 0 4,330 55 4,712 48 4,263 18 4,455 8 5,286 24 4,662 0 CER-Constant Exchange Rates; ' versus same period of prior year; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF. 188#189HY 2022: Diagnostics Division regional sales Growth driven by Asia Pacific and North America Sales YTD CHFm & % of total sales Total YTD Sales = 9,948 Sales growth at CER Diagnostics Division GLOBAL 559 6% 3,350 / 33% 3,171/ 32% 2,868 / 29% EMEA* ■NAM APAC ■ LATAM CER-Constant Exchange Rates (avg. full year 2021); * Europe, Middle East and Africa 11% -14% EMEA* 34% NAM 39% APAC | 2% LATAM Roche 189#190Core Lab CHFbn 4.8 4.0 3.2 2.4 1.6 0.8 2022 vs. 2021 CER growth +4% HY 2022 0.0 HY 2020 HY 2021 Immunodiagnostics Clinical Chemistry CER=Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +4% Other -7% +8% +6% Roche 190#191Point of Care CER-Constant Exchange Rates CHFbn 2.8 2.4 2.0 1.6 1.2 0.8 0.4 0.0 HY 2020 HY 2021 Clinical Chem. & Immunodiagn. Coagulation & Urinalysis 2022 vs. 2021 CER growth +46% HY 2022 Hospital Glucose POC MDX +75% -8% -9% +54% Roche 191#192Molecular Lab CER-Constant Exchange Rates CHFbn 2.4 1.8 1.2 0.6 0.0 2022 vs. 2021 CER growth +1% +29% -18% -2% +19% -15% +4% +4% ■ Virology HY 2020 | Cervical Cancer HY 2021 Blood Screening qPCR&NAP HY 2022 MD Systems Other ■Microbiology Roche 192#193Diabetes Care CER-Constant Exchange Rates CHFbn 1.0 0.8 0.6 0.4 0.2 0.0 HY 2020 HY 2021 Blood Glucose Monitoring 2022 vs. 2021 CER growth -5% HY 2022 Other +18% -7% Roche 193#194Pathology Lab CER-Constant Exchange Rates CHF bn 0.8 2022 vs. 2021 CER growth +10% 0.6 0.4 0.2 0.0 HY 2020 HY 2021 Advanced Staining Primary Staining +26% +2% +9% HY 2022 Companion Diagnostics Roche 194#195Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Spark Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information Roche#196CHF/USD 1.00 0.90 0% Monthly averages 7% 0.80 T Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec -2021 -2022 1.00 0.90 2% Year-To-Date averages 4% Roche 0.80 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 -2022 196#197CHF/USD 1.00 0.98 0.96 0.94 0.92 0.90 0.88 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg full year 2021 avg full year 2022 monthly avg 2021 monthly avg 2022 HY 2022 3% Roche 197#198CHF/EUR 1.10 -7% Monthly averages -6% 1.05 1.00 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 2022 1.10 Year-To-Date averages -5% -6% 1.05 Roche 1.00 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2021 -2022 198#199CHF/EUR 1.12 1.10 1.08 1.06 1.04 1.02 1.00 Jan Feb Mar Apr May avg full year 2021 avg full year 2022 Jun Jul Aug Sep Oct Nov Dec monthly avg 2021 - monthly avg 2022 HY 2022-5% Roche 199#200Average CHF Exchange Rates HY 2022 HY 2021 HY 2022 vs. HY 2021 USD 0.94 0.91 EUR 1.03 1.09 -6% JPY 0.77 0.84 -9% 4% Roche -10% -5% 0% 5% 10% 200#201Exchange rate impact on sales growth Q2 2022: negative impact of JPY and EUR, positive impact of USD Development of average exchange rates versus prior year period CHF / USD CHF/EUR 2.2% 5.9% -4.9% -6.4% CHF/JPY -6.9% -10.6% Difference in CHF / CER -1.0% 0.4% growth Sales growth 2022 vs. 2021 11.2% 10.2% 0.0% 0.4% CER growth CHF growth Q1 Q2 Q3 80 CER = Constant Exchange Rates (avg full year 2021) Q4 Roche 201#202Exchange rate impact on sales growth HY 2022: negative impact of JPY and EUR, positive impact of USD Development of average exchange rates versus prior year period CHF / USD CHF/EUR 2.2% 4.0% -4.9% -5.7% CHF/JPY -6.9% -8.9% Difference in CHF / CER -1.0% -0.2% growth Sales growth 2022 vs. 2021 11.2% 10.2% 5.4% 5.2% CER growth CHF growth Q1 HY YTD Sep FY CER = Constant Exchange Rates (avg full year 2021) Roche 202#203Doing now what patients need next